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CHAIN-MODIFIED PYRIDINO-N 
SUBSTITUTED NICOTINE COMPOUNDS 
FOR USE IN THE TREATMENT OF CNS 
PATHOLOGIES 
RELATED APPLICATIONS 
This application claims priority from US. Provisional 
Patent Application Ser. No. 60/342,120, ?led Dec. 26, 2001. 
FIELD OF THE INVENTION 
This invention relates to chain-modi?ed analogs of N-n 
octylnicotinium iodide (NONI) and N-n-decylnicotinium 
iodide (NDNI) that have selective (x3 [32* and (>t4[32 nicotinic 
receptor antagonist properties respectively, and to a method 
of using such compounds to treat central nervous system 
pathologies. The present invention also relates to pharma 
ceutical compositions containing these compounds, as Well 
as various uses thereof. 
BACKGROUND OF THE INVENTION 
Formula (I) beloW shoWs the structure of S-(—)-nicotine 
(NIC), Which activates neuronal nicotinic receptors evoking 
release of dopamine (DA) from presynaptic terminals in the 
central nervous system (CNS). NIC is a legal substance of 
dependence that produces many of its effects on the CNS, 
some of Which may be considered to be bene?cial e.g., mood 
elevation, arousal and learning and memory enhancement. 
NIC produces its effect by binding to a family of ligand 
gated ion channels, stimulation by acetylcholine (ACh) or 
NIC causes the ion channel to open, and cations to ?ux With 
a resulting rapid (in millisec) depolariZation of the target 
cell. 
Over the last 12 years, there has been a substantial 
increase in studies on brain nicotinic receptors. Adult 
peripheral nicotinic muscle receptors are composed of four 
subunit domains: 2a, [3, y and 6. Traditional peripheral 
nicotinic receptor antagonists are shoWn in formula (II) and 
(III), i.e. decylmethonium (DEC) (muscle), hexamethonium 
(HEX) (ganglionic), and d-tubocurarine (d-Tc) (muscle). 
These compounds have also shoWn the ability to Weakly 
inhibit neuronal nicotinic receptors. 
Neuronal nicotinic receptors are composed of only tWo 
subunits, 0t and [3 and are believed to assemble With the 
general stoichiometry of 2a and 3[3. Nine subtypes of the ot 
subunit (a2 to (x10) and three subtypes of the [3 unit ([32 to 
[34) are found in CNS. The most common nicotinic receptor 
species in the brain is composed of tWo (X4 and three [32 
subunits, i.e., (X462. These subunits display different, but 
overlapping, patterns of expression in the brain. 
For the most part, the actual subunit compositions and 
stoichiometries of nicotinic receptors in the brain remain to 
be elucidated. Thus, neuronal nicotinic receptor subtype 
diversity originates from differences in the amino acid 
sequence at the subunit level and from the multiple combi 
nations of assemblies of subunits, Which can form functional 
receptor proteins. 
In spite of the extensive diversity in neuronal nicotinic 
receptor messenger RNA expression, only a limited number 
of tools are available to study the pharmacology of native 
receptors. Radioligands are used in many such studies. 
[3H]NIC appears to label the same sites in the brain as 
[3H]ACh. It has been estimated that over 90% of [3H]NIC 
binding in the brain is due to association With the hetero 
meric receptor that is composed of (X4 and [32 subunits. Also 
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abundant in the CNS, are the receptors labeled by [3Hmeth 
yllycaconitine (MLA), Which has high af?nity for the (X7 
homomeric nicotinic receptor subtype. Additionally, nico 
tinic receptor subtypes can be studied using functional 
assays such as NIC-evoked [3H]dopamine (DA) release 
from rat striatal slices. Nicotinic receptors are located on the 
cell body and terminals of the nigrostiatal pathWay. NIC 
facilitates DA release from striatal nerve terminals. Studies 
strongly suggest that the [3H]DA release assay is useful to 
probe (x3 [32* nicotinic receptor subtypes. 
Structural and functional diversity of CNS nicotinic 
receptors has stimulated a great deal of interest in develop 
ing novel, subtype-selective agonists. Some of these ago 
nists are currently being evaluated in clinical trials for 
cognitive enhancement and neuroprotective effects poten 
tially bene?cial for disease states such as AlZheimer’s and 
Parkinson’s Disease. Surprisingly, little attention has been 
focused on developing subtype-selective antagonists for 
neuronal nicotinic receptors. Potential uses of nicotinic 
receptor anatagonists are for the treatment of psychostimu 
lant abuse, smoking cessation, and schizophrenia. 
A class of pyridino N-substituted nicotine analogs having 
formula (IV) beloW are knoWn antagonists that have a?inity 
in the [3H]NIC binding assay and demonstrate the ability to 
inhibit NIC-evoked [3 H] DA release. The abbreviated 
nomenclature is given in parentheses. 
\ \\\\‘ 
I CH3 / 
N 
H 
iHg iHg 
BNVWVNQ H3C [ " [ CH3 
CH3 CH3 
2 C16 
2.) n I 4 (HEX) 
b) n I 8 (DEC) 
III 
oCH3 
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-continued 
a.) R I (CH2)7CH3 (NONI) 
b) R I (cnmcn3 (NNNI) 
c) R I (cnmcn3 (NDNI) 
d) R I (CH2)10CH3 (NUNI) 
e) R I (CH2)11CH3 (NDDNI) 
These compounds are useful in the treatment of nicotine 
abuse, smoking cessation therapy, as an antidote for nicotine 
intoxication, treatment of cognitive disorders such as AlZhe 
imer’s disease and for the treatment of Parkinson’s disease. 
These compounds and their method of use Were the subject 
of US. Pat. No. 5,691,365, issued Nov. 25, 1997. The 
content of this patent is incorporated herein by reference. 
The invention disclosed herein is directed to a series of 
ef?cacious and subtype-selective nicotinic antagonists at 
nicotinic receptors in the CNS. These compounds comprise 
alkenyl alkynyl, branched and cyclic pyridine-N substituted 
NIC analogs. 
SUMMARY OF THE INVENTION 
The present invention provides for chain-modi?ed ana 
logs of N-n-octylnicotinium iodide (NONI) and N-n-de 
cylnicotinium iodide (NDNI) having potent and selective 
antagonistic activity at certain neuronal nicotinic receptor 
subtypes. These compounds competitively inhibit CNS 
nicotinic receptor agonists and act at (x3 [32* or (x462 neuronal 
nicotinic receptor subtypes in the CNS. 
A preferred embodiment of the invention provides for a 
method of antagoniZing the nicotinic receptor comprising 
administering of a pharmaceutically e?‘ective amount of a 
compound of the invention. 
Still another embodiment the invention provides a method 
for the treatment of psychostimulant abuse (including nico 
tine abuse, amphetamine abuse, methamphetamine abuse, 
and cocaine abuse), alcohol abuse, as a smoking cessation 
therapy, as an antidote for nicotine intoxication comprising 
administering of a pharmaceutically e?‘ective amount of a 
compound according to the invention, as a therapeutic agent 
for the treatment of pathologies of the GI tract, including 
irritable boWel syndrome, colitis and related disorders. 
This invention further provides a method of treatment of 
CNS disorders associated With the alteration of normal 
neurotransmitter release in the brain, including conditions 
such as AlZheimer’s disease as Well as other types of 
dementia, Parkinson’s disease, cognitive dysfunction (in 
cluding disorders of attention, focus and concentration), 
attention de?cit syndrome, a?fective disorders, mood and 
emotional disorders such as depression, panic anxiety and 
psychosis, Tourette’s syndrome, schizophrenia, eating dis 
orders and the control of pain comprising administering of 
a pharmaceutically e?‘ective amount of a compound accord 
ing to the invention. 
The above and other objects of the invention Will become 
readily apparent to those of skill in the relevant art from the 
folloWing detailed description and ?gures, Wherein only the 
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4 
preferred embodiments of the invention are shoWn and 
described, simply by Way of illustration of the best mode of 
carrying out the invention. As is readily recogniZed the 
invention is capable of modi?cations Within the skill of the 
relevant art Without departing from the spirit and scope of 
the invention. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention provides novel compounds, includ 
ing resolved enantiomers and diastereoisomers, having a 
formula selected from formula (V) or formula (VI) beloW: 
(V) 
(VI) 
Wherein 
Q is selected from the group consisting of a straight chain 
or branched alkylene group having 1% carbon atoms, a 
substituted alkenylene group having 1I3 carbon atoms, 
C(O), O, C(S), S, S(O) and S(O)2 containing alkylene 
moiety, provided that any heteroatom contained in Q is 
separated from N by at least one carbon atom; 
R1 is selected from the group consisting of hydrogen, 
loWer straight chain or branched alkyl, cycloalkyl having 
1I6 carbon atoms, substituted cycloalkyl having 1I6 carbon 
atoms, aryl, aralkyl, or heterocyclic group; 
R2, Z1 and Z4 are each independently selected from the 
group consisting of hydrogen, loWer alkyl, loWer branched 
alkyl, loWer alkenyl, and loWer branched alkenyl; 
A and B are selected from nitrogen or carbon With the 
proviso that When A or B is nitrogen, R3 or R4 cannot be 
present; 
R3, R4, Z2 and Z3 are each independently selected from 
the group consisting of hydrogen; alkyl; substituted alkyl; 
cycloalkyl; substituted cycloalkyl; substituted alkenyl; sub 
stituted alkenyl; alkynyl; substituted alkynyl; aryl; substi 
tuted aryl; alkylaryl; substituted alkylaryl; arylalkyl; substi 
tuted arylalkyl; arylalkenyl; substituted arylalkenyl; 
arylalkynyl; substituted arylalkynyl; heterocyclic; substi 
tuted heterocyclic; tri?uoromethyl; halogen; cyano; nitro; 
S(O)Yl, S(O)2Yl, S(O)2OY' or S(O)2NHY1, Wherein each 
Y is independently hydrogen, loWer alkyl, alkenyl, alkynyl 
or aryl, With the proviso that When R3, R4 or R5 is S(O)Y1, 
US 7,091,357 B2 
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Y1 is not hydrogen, and With the further proviso that When 
Y1 is alkenyl or alkynyl, the site of unsaturation is not 
conjugated With a heteroatom; C(O)Y2, Wherein Y2 is 
selected from hydrogen, alkyl, substituted alkyl, alkoxy, 
alkylamino, alkenyl, substituted alkenyl, alkynyl, substi 
tuted alkynyl, aryl, substituted aryl, aryloxy, arylamino, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla 
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub 
stituted arylalkynyl, heterocyclic, substituted heterocyclic or 
tri?uoromethyl, With the proviso that the carbonyl function 
ality is not conjugated With an alkenyl or alkynyl function 
ality; OY3 or N(Y3)2 Wherein each Y3 is independently 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi 
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
heterocyclic, substituted heterocyclic, acyl, tri?uoromethyl, 
alkylsulfonyl or arylsulfonyl, With the proviso that OY3 or 
N(Ys)2 functionality is not conjugated With an alkenyl or 
alkynyl functionality; SY4 Wherein Y4 is selected from 
hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted 
cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted 
alkynyl, aryl, substituted aryl, alkylaryl, substituted alky 
laryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi 
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het 
erocyclic, substituted heterocyclic or tri?uoromethyl, With 
the proviso that the SY4 functionality is not conjugated With 
an alkenyl or alkynyl functionality; or R3 and R4 together 
form a three to eight membered saturated or unsaturated 
ring, Wherein from one to three carbon atoms of said ring 
may optionally and independently be replaced by a nitrogen, 
oxygen or sulfur atom, and Wherein said rings may option 
ally be substituted With one or more substituents that are 
de?ned as Z3 and Z4; or either Z1 and Z2 or Z1 and Z3 
together form a fused ring structure; or either Z2 and Z4 Z3 
and Z4 together form a spiro ring structure; 
R5 is selected from the group consisting of alkyl; substi 
tuted alkyl; cycloalkyl; substituted cycloalkyl; alkenyl; sub 
stituted alkenyl; alkynyl; substituted alkynyl; aryl; substi 
tuted aryl; arylalkyl; substituted arylalkyl; arylalkenyl; 
substituted arylalkenyl; arylalkynyl; substituted arylalkynyl; 
heterocyclic; substituted heterocyclic; S(O)Yl', S(O)2Yl, 
S(O)2OYl or S(O)2NHYl, Wherein each Y1 is independently 
hydrogen, loWer alkyl, alkenyl, alkynyl or aryl, With the 
proviso that When R3, R4 or R5 is S(O)Y1, Y1 is not 
hydrogen, and further With the proviso that When Y1 is 
alkenyl or alkynyl, the site of unsaturation is not conjugated 
With a heteroatom; C(O)Y2, Wherein Y2 is selected from 
hydrogen, alkyl, substituted alkyl, alkoxy, alkylamino, alk 
enyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, 
substituted aryl, aryloxy, arylamino, alkylaryl, substituted 
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, sub 
stituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
heterocyclic, substituted heterocyclic or tri?uoromethyl, 
With the proviso that the carbonyl functionality is not 
conjugated With an alkenyl or alkynyl functionality; OY3 or 
N(Y3)2 Wherein each Y3 is independently selected from 
hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted 
cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted 
alkynyl, aryl, substituted aryl, alkylaryl, substituted alky 
laryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi 
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het 
erocyclic, substituted heterocyclic, acyl, tri?uoromethyl, 
alkylsulfonyl or arylsulfonyl, With the proviso that the OY3 
or N(Y3)2 functionality is not conjugated With an alkenyl or 
alkynyl functionality; SY4 Wherein Y4 is selected from 
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hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted 
cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted 
alkynyl, aryl, substituted aryl, alkylaryl, substituted alky 
laryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi 
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het 
erocyclic, substituted heterocyclic or tri?uoromethyl, With 
the proviso that the SY4 functionality is not conjugated With 
an alkenyl or alkynyl functionality; and With the further 
proviso that When A and B are carbon, R5 is not N-alkyl or 
branched alkyl With 2*l 9 carbon atoms, cycloalkyl, aralkyl, 
N-alkenyl or alkenyl With 2*l9 carbon atoms, or N-alkynyl 
or branched alkynyl With 2 to 19 carbon atoms; 
R6 is hydrogen; 
X is selected from the group consisting of Cl, Br, I, HSO4, 
1/2802, CH3SO3, p-TsO and CF3SO3; and 
Y is selected from the group consisting of 2C1, 2Br, 2l, 
2HSO4, S02, 2CH3SO3, 2p-TsO and 2CF3SO3. 
When R3 and R4 together form a three to eight membered 
saturated or unsaturated ring or either 1 and Z2 or 1 and Z3 
together form a fused ring structure, the fused ring or 
saturated or unsaturated ring selected from the group con 
sisting of benZene, pyridine, pyran, indene, isoindene, ben 
Zofuran, isobenZofuran, benZo[b]thiophene, benZo[c] 
thiophene, indole, indolenine, isoindole, cyclopental[b] 
pyridine, pyrano[3,4-b]pyrrole, indaZole, indoxaZine, 
benZosaZole, anthranil, naphthalene, tetralin, decalin, 
chromene, coumarin, chroman-4-one, isocoumarin, isoch 
romen-3-one, quinoline, isoquinoline, cinnoline, quinaZo 
line, naphthyridine, pyrido[3,4-b]-pyridine, pyridol[3,2-b] 
pyridine, pyrido[4,3-b]-pyridine, benZoxaZine, anthracene, 
phenanthrene, phenalene, ?uorene, caraZole, xanthene, acri 
dine, octahydro-[l]pyridine, l-methyl octahydro-[l]pyri 
dine, octahydro-indole, l-methyl octahydro-indole, octahy 
dro-cyclopenta[b]pyrrole, l-methyl-octahydrocyclopenta[b] 
pyrrole, dec ahydro -quinoline, and 1 -methyl - 
decahydroquinoline. 
It is preferred that Q is either CH2, CH2CH2, CH=CHi, 
C(CH3)=CH, CH=(C(CH3), or C(CH3)=C(CH3); A and 
B are each carbon; R1 is a CFC1O alkyl or more preferably 
a CFC6 alkyl alkyl or even more preferably a CFC4 alkyl 
such as methyl, ethyl, isopropyl or isobutyl; R2 is hydrogen; 
R3 and R4 are individually selected from the group consist 
ing of hydrogen, halogen, alkyl or alkanoyl; R5 is a branched 
or non-branched C(Cl9 alkyl, cycloalkyl, alkenyl, alkynyl, 
aryl, arylalkyl arylalkenyl, arylalknyl; Z1, Z2, Z3 and Z4 are 
each hydrogen, or Z3 and Z4 are hydrogen, Z1 and Z2 and 
their associated carbon atoms combine to form a ?ve or six 
membered fused ring structure, or Z2 and Z4 are hydrogen, 
Z1 and Z3 and their associated carbon atoms combine to 
form a ?ve or six membered fused ring structure, or Z1 and 
Z3 are hydrogen, Z2 and Z4 and their associated carbon 
atoms combine to form a ?ve or six membered spiro ring 
structure, or Z1 and Z2 are hydrogen, Z3 and Z4 and their 
associated carbon atoms combine to form a ?ve or six 
membered spiro ring structure; and X is iodine or bromine. 
As employed herein, the meaning of the aforementioned 
terms are de?ned as folloWs: 
“loWer alkyl” refers to straight or branched chain alkyl 
radicals having in the range of about 1 up to 4 carbon atoms; 
“alkyl” refers to straight or branched chain alkyl radicals 
having in the range of about 1 up to 19 carbon atoms and 
“substituted alkyl” refers to alkyl radicals further bearing 
one or more substituents such as hydroxy, alkoxy (of a loWer 
alkyl group), mercapto (of a loWer alkyl group), aryl, 
heterocyclic, halogen, tri?uoromethyl, cyano, nitro, amino, 
carboxyl, carbamate, sulfonyl, sulfonamide, and the like. 
US 7,091,357 B2 
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“cycloalkyl” refers to cyclic ring-containing moieties 
containing in the range of about 3 up to 8 carbon atoms and 
“substituted cycloalkyl” refers to cycloalkyl moieties further 
bearing one or more substituent as set forth above; 
“alkenyl” refers to straight or branched chain hydrocarbyl 
groups having at least one carbon-carbon double bond, and 
having in the range of about 2 up to 19 carbon atoms and 
“substituted alkenyl” refers to alkenyl groups further bearing 
one or more substituents as set forth above; 
“alkynyl” refers to straight or branched chain hydrocarbyl 
moieties having at least one carbon-carbon triple bond, and 
having in the range of about 2 up to 19 carbon atoms and 
“substituted alkynyl” refers to alkynyl moieties further bear 
ing one or more substituents as set forth above; 
“aryl” refers to aromatic groups having in the range of 6 
up to 24 carbon atoms and “substituted aryl” refers to aryl 
groups further bearing one or more substituents as set forth 
above; 
“alkylaryl” refers to alkyl-substituted aryl groups and 
“substituted alkylaryl” refers to alkylaryl groups further 
bearing one or more substituents as set forth above; 
“arylalkyl” refers to aryl-substituted alkyl groups and 
“substituted arylalkyl” refers to arylalkyl groups further 
bearing one or more substituents as set forth above; 
“arylalkenyl” refers to aryl-substituted alkenyl groups and 
“substituted arylalkenyl” refers to arylalkenyl groups further 
bearing one or more substituents as set forth above; “ary 
lalkynyl” refers to aryl-substituted alkynyl groups and “sub 
stituted arylalkynyl” refers to arylalkynyl groups further 
bearing one or more substituents as set forth above; 
“aroyl” refers to aryl-substituted species such as benZoyl 
and “substituted aroyl” refers to aroyl moieties further 
bearing one or more substituents as set forth above; 
“heterocyclic” refers to cyclic moieties containing one or 
more heteroatoms as part of the ring structure, and having in 
the range of 3 up to 24 carbon atoms and “substituted 
heterocyclic”refers to heterocyclic moieties further bearing 
one or more substituents as set forth above; “acyl” refers to 
alkyl-carbonyl species; 
“halogen” refers to ?uoride, chloride, bromide or iodide 
groups. 
Examples of pharmaceutically acceptable salts include 
inorganic and organic acid addition salts such as hydrochlo 
ride, hydrobromide, nitrate, sulfate, phosphate, acetate, 
methanesulfonate, p-toluenesulfonate, benZenesulfonate, 
salicylate, propionate, ascorbate, aspartate, fumarate, galac 
tarate, maleate, citrate, glutamate, glycolate, lactate, malate, 
maleate, tarrate, oxalate, succinate, or similar pharmaceuti 
cally-acceptable inorganic or organic acid addition salts, and 
include the pharmaceutically acceptable salts listed in the 
Journal ofPharmaceuZical Science, 66, 2. (1977) Which are 
hereby incorporated by reference. The above salt forms may 
be in some cases hydrates or solvates With alcohols and other 
solvents. 
When used in reference to compounds of the invention, 
“an effective amount” refers to doses of compound suf?cient 
to provide circulating concentrations high enough to impart 
a bene?cial effect on the recipient thereof for alleviating a 
disease or pathological symptom of a CNS pathology. The 
amount to be administered depends to some extent on the 
lipophilicity of the speci?c compound selected, since it is 
expected that this property of the compound Will cause it to 
partition into fat deposits of the subject. The precise amount 
to be administered can be determined by the skilled practi 
tioner in vieW of desired dosages, side effects and medical 
history of the patient and the like. It is anticipated that the 
compound Will be administered in the amount ranging 
1><10 to about 100 mg/kg/day, With amounts in the range of 
about 1><10_2 up to 1 mg/kg/day being preferred. 
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A pharmaceutical composition containing a compound of 
the invention is also contemplated, Which may include a 
conventional additive, such as a stabiliZer, bulfer, salt, 
preservative, ?ller, ?avor enhancer and the like, as knoWn to 
those skilled in the art. Representative bulfers include phos 
phates, carbonates, citrates and the like. Exemplary preser 
vatives include EDTA, EGTA, BHA, BHT and the like. A 
composition of the invention may be administered by inha 
lation, i.e., intranasally as an aerosol or nasal formulation; 
topically, i.e., in the form of an ointment, cream or lotion; 
orally, i.e., in solid or liquid form (tablet, gel cap, time 
release capsule, poWder, solution, or suspension in aqueous 
or non aqueous liquid; intravenously as an in?sion or 
injection, i.e., as a solution, suspension or emulsion in a 
pharmaceutically acceptable carrier, transdermally, e.g., via 
a transdermal patch; rectally as a suppository and the like. 
The present invention includes all possible diastereomers 
and all enantiomeric forms as Well as racemic mixtures. The 
compounds can be separated into substantially optically pure 
compounds. The compounds of the invention are nicotinic 
receptor agents. They inhibit [3H]NIC binding and [3 H] 
MLA binding and NlC-evoked [3H]DA release. 
Examples of compounds falling Within the scope of the 
present invention precede the appended claims. If one spe 
ci?c enantiomer is shoWn or described, the other enantiomer 
may readily be made from the appropriate chiral precursor 
or can be resolved from a racemic mixture. 
VI 
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(S) -trans -3 -(1-Methyl-pyrolidin-2-yl)-1-oct-3 -enyl-pyridu 
ium bromide hydrobromide salt (NONB -3t); 
(S) -trans-1 -Dec -4-enyl-3 ( 1 -methyl-pyrrolidin-2 -yl)-pyri 
dinium bromide (NDNB-4t); 60 
(S) -cis-3 -(1-Methyl-pyrrolidin-2-yl)-1-oct-3 -enyl-pyri 
dinium bromide hydrobromide salt (N ONE -3 c); 
(S) -cis-1 -Dec -4 -enyl-3 -(1-methyl-pyrrolidin-2-yl)-pyri 
dinium bromide hydrobromide salt (N DNB -4c); 
(S) -3 -(1-Methyl-pyrrolidin-2-yl)-1-oct-7-enyl 
bromide (N ONB-7e); 
-pyridinium 
1 0 
(S)-1-Dec-9-enyl-3 -(1-methyl-pyrrolidin-2-yl)-pyridinium 
bromide (N DNB-9e); 
(S)-3 -(1-Methyl-pynolidin-2-yl)-1-undec-10-enyl-pyri 
dinium bromide (NU NB- 1 0e); 
(S)-1-(6-Cyclobutyl-hexyl)3 -(1-methyl-pyrrolidin-2-yl)-py 
ridinium bromide hydrobromide salt (N CyNB -4); 
(S)-1-(6-Cyclopentyl-hexyl)-3 -(1-methyl-pyrrolidin-2-yl) 
pyridinium bromide hydrobromide salt (NCyNB-5); 
(S)-1-(6-Cyclohexyl-hexyl)-3 -(1-methyl-pyrrolidin-2-yl) 
pyridmium bromide hydrobromide salt (NCyNB-6); 
(S)-3 -(1-Methyl-pyrrolidin-2-yl)-1-oct-3 -ynyl-pyridinium 
bromide (N ONB -3y); 
(S)-1-Dec-3 -ynyl-3 -(1-methyl-pyrrolidin-2-yl)pyridinium 
bromide (N DNB -3y); 
(S)-1-(7-Methyl-oct-6-enyl)-3 -(1-methyl-pyrrolidin-2-yl) 
pyridinium bromide hydrobrormide (NONB-6e7M); 
(S)-1-(7-Methyl-octyl)-3 -(1-methyl-pyrrolidin-2-yl)-pyri 
dinium bromide hydrobromide salt (N ONB-7M); 
(S)-1-[2-(2-Ethoxy-ethoxy)-ethyl]-3-(1-methyl-pyrrolidin 
2-yl)-pyridinium bromide (NONB -3060); 
(S)-1-(9-Acetoxy-nonyl)-3 -(1-methyl-pyrrolidin-2-yl)-pyri 
dinium bromide (N ANNB); 
(S)-1-(11-Acetoxy-undecyl)-3 -(1-methyl-pyrrolidin-2-yl) 
pyridinium bromide (NAUNB); 
(S)-1-(12-Acetoxy-dodecyl)-3 -(1-methyl-pyrrolidin-2-yl) 
pyridinium bromide (NADDNB); 
These compounds can be prepared from corresponding 
free bases by reaction With an appropriate alkyl iodide using 
techniques knoWn to those skilled in the art of organic 
synthesis. 
The invention Will noW be described in greater detail by 
reference to the folloWing non-limiting examples. 
EXAMPLE 1 
(S)-trans-3-(1-Methyl-pyrrolidin-2-yl)-1-oct-3-enyl 
pyridinium bromide hydrobromide salt (NONB-3t) 
1a. trans-Oct-3-en-1-ol 
A solution of oct-3-yn-1-ol (2.52 g, 20.0 mmol), t-BuOH 
(5 g), THF (10 mL) and liquid NH3 Was cooled to —360 C. 
Pieces of Lithium (0.34 g, 50 mmol) Were introduced With 
vigorous stirmg and maintaining the temperature. After 2 h, 
NH3 Was alloWed to evaporate overnight. Saturated NH4Cl 
solution Was added and the reaction mixture Was extracted 
With hexane. The combined organic layers Were Washed 
With 1 M HCl, aqueous NaHCO3 and brine successively and 
dried. Evaporation of the solvent gave trans-oct-3-en-1-ol 
(2.44 g, 95%) as a pale yelloW oil, Which Was used in the 
next step Without further puri?cation: 1H NMR (300 MHZ, 
CDCl3) 6 5.54 (1H, m), 5.36 (1H, m), 3.66 (2H, t, JI6.3 HZ), 
2.25 (2H, m), 2.02 (2H, m), 1.74 (1H, br s), 1.31 (4H, m), 
0.88 (3H, t, JI7.2 HZ); 13C NMR (75 MHZ, CDCl3) 6 
134.27, 125.78, 62.22, 36.22, 32.59, 31.86, 22.47, 14.20. 
1b. trans-1-Bromo-oct-3-ene 
To a solution of trans-oct-3-en-1-ol (1.28 g, 10.0 mmol) 
in DMF (25 mL) Was added triphenylphosphine (2.92 g, 
11.1 mmol). The solution Was cooled to 00 C. and NBS (1.92 
g, 10.8 mmol) Was added in portions. After stirring for 30 
min at room temperature, the reaction Was quenched With 
methanol (1 mL). The solution Was diluted With ether (100 
mL), Washed With Water, saturated aqueous NaHCO3 and 
brine successively. The organic layer Was dried and concen 
trated. The residue Was puri?ed by ?ash chromatography on 
silica gel, eluting With hexane to afford trans-1-bromo-oct 
3-ene (1.40 g, 73%) as a colorless oil: 1H NMR (300 MHZ, 
CDCl3) 6 5.54 (1H, m), 5.39 (1H, m), 3.37 (2H, t, JI7.2 HZ), 
US 7,091,357 B2 
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2.54 (2H, m), 2.02 (2H, m) 1.34 (4H, m), 0.89 (3H, 1, 1:72 
HZ); 13C NMR (75 MHZ, CDC13) 0 134.09, 126.45, 36.34, 
33.21, 32.48, 31.73, 22.45, 14.24. 
1c. (S)-trans-3-(1-Methyl-pyrrolidin-2-yl)-1-oct-3enyl-pyri 
dinium bromide hydrobromide salt (NONB-3t) 
To a stirred solution of (S)-nicotine (0.46 g, 2.8 mmol) in 
AcOH (10 ml) Was added trans-1-bromo-oct-3-ene (1.37 g, 
7.17 mmol). The mixture Was heated at re?ux for 3 days. 
AcOH Was evaporated and the residue Was recrystallized in 
ethyl acetate-CHCl3 to afford (S)-trans-3-(1-methyl-pyrroli 
din-2-yl)-1-oct-3 -enyl-pyridinium bromide hydrobromide 
salt (NONB-3t) (0.76 g, 62%) as hygroscopic White crystals: 
1H NMR (300 MHZ, CDCl3) 6 11.55 (1H, s), 10.27 (1H, s), 
9.46 (1H, d, J:7.5 HZ), 9.16 (1H, d, 1:57 HZ), 8.22 (1H, dd, 
J:7.5, 5.7 HZ), 5.72 (1H, m), 5.41 (2H, m), 4.88 (2H, m), 
3.98 (1H, m), 3.38 (1H, m), 2.94 (3H, s), 26042.90 (3H, m), 
2.43 (3H, m), 1.86 (2H, m), 1.004125 (4H, m), 0.79 (3H, t, 
J:7.2 HZ); 13C NMR (75 MHZ, CDCl3) 6 147.29, 146.41, 
145.11,137.58, 134.31,128.44, 122.37, 67.18, 62.27, 56.04, 
38.57, 34.49, 32.30, 32.00, 31.41, 22.32, 21.83, 14.12; Anal. 
Calcd for Cl8H3OBr2N2.0.3H2O: C, 49.22; H, 6.93; N, 6.38. 
Found: C, 49.25; H, 7.03; N, 6.30. 
EXAMPLE 2 
-trans- - ec- -eny - - -met y -pyrro1 in- -y - S 1 D 4 l 3 1 h 1 d 2 l 
pyridinium bromide (N DNB-4t) 
2a. trans-Dec-4-en-1-ol 
Sodium borohydride (0.60 g, 3.8 mmol) Was added in 
portions to a stirred solution of trans-dec-4-enal (1.54 g, 10.0 
mmol) in methanol (50 mL). The reaction Was stirred at 
room temperature for 30 min folloWed by the addition of 
saturated NH4Cl. Methanol Was evaporated and Water Was 
added to the residue. The mixture Was extracted With ether 
and the combined organic layers Were Washed With Water 
and dried. Evaporation of the solvent gave trans-dec-4-en 
1-ol (1.52 g, 97%) as a pale yelloW oil, Which Was used in 
the next step Without further puri?cation: 1H NMR (300 
MHZ, CDCl3) 6 5.39 (2H, m), 3.60 (2H, t, 1:66 HZ), 2.02 
(5H, m), 1.56 (2H, m), 1.23 (6H, m), 0.84 (3H, t, 1:69 HZ); 
13C NMR (75 MHZ, CDCl3) 6 131.31, 129.44, 62.66, 32.80, 
32.70, 31.67, 29.51, 29.18, 22.82, 14.36. 
2b. trans-1-Bromo-dec-4-ene 
To a solution of trans-dec-4-en-1-ol (1.52 g, 9.74 mmol) 
in DMF (25 mL) Was added triphenylphosphine (2.81 g, 
10.7 mmol). The solution Was cooled to 00 C. and NBS (1.85 
g, 10.4 mmol) Was added in portions. After stirring for 30 
min at room temperature, the reaction Was quenched With 
methanol (1 mL). The solution Was diluted With ether (100 
mL), Washed With Water, saturated aqueous NaHCO3 and 
brine successively. The organic layer Was dried and concen 
trated. The residue Was puri?ed by ?ash chromatography on 
silica gel, eluting With hexane to afford trans-l-bromo-dec 
4-ene (1.60 g, 75%) as a colorless oil: 1H NMR (300 MHZ, 
CDCl3) 6 5.49 (1H, m), 5.35 (1H, m), 3.42 (2H, t, 1:66 HZ), 
2.15 (2H, m), 1.96 (4H, m), 1.29 (6H, m), 0.90 (3H, t, J:7.2 
HZ); 3C NMR (75 MHZ, CDCl3) 6 132.36, 127.89, 33.61, 
32.80, 32.73, 31.65, 31.14, 29.45, 22.82, 14.36. 
2c. (S)-trans-1-Dec-4-enyl-3-(1-methyl-pyrrolidin-2-yl)-py 
ridinium bromide (N DNB-4t) 
To a stirred solution of (S)-nicotine (0.47 g, 2.9 mmol) in 
AcOH (15 ml) Was added trans-1-bromo-dec-4-ene (1.55 g, 
7.08 mmol). The mixture Was heated at re?ux for 3 days. 
AcOH Was evaporated and the residue Was dissolved in 
CHCl3. The mixture Was Washed With saturated aqueous 
NaHCO3, Water and brine successively and dried. Evapora 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
12 
tion of the solvent folloWed by titration With ether afforded 
0.82 g (74%) of (S)-trans-1-dec-4-enyl-3-(1-methyl-pyrro 
lidin -2-yl)-1-pyridinium bromide (NDNB-4t) as a broWn 
oil. 1H NMR (300 MHZ, CDCl3) 6 9.71 (1H, d, J:5.7 HZ), 
9.07 (1H, s), 8.40 (1H, d, 1:81 HZ), 8.08 (1H, dd, 1:81, 6.0 
HZ), 5.42 (2H, m), 5.00 (2H, t, 1:69 HZ), 3.54 (1H, t, J:8.4 
HZ), 3.25 (1H, m), 2.44 (2H, m), 2.25 (3H, s), 16542.20 
(8H, m), 1.66 (1H, m), 1.154140 (6H, m), 0.87 (3H, t, J:7.2 
HZ); 13C NMR (75 MHZ, CDCl3) 6 146.50, 144.36, 143.79, 
143.13, 128.52, 127.15, 67.05, 61.49, 56.86, 40.70, 36.07, 
32.67, 31.76, 31.56, 29.27, 29.07, 23.39, 22.70, 14.27; Anal. 
Calcd for C2OH33BrN2.0.3H2O: C, 62.10; H, 8.76; N, 7.24. 
Found: C, 62.03; H, 8.88; N, 7.12. 
EXAMPLE 3 
(S)-cis-3 -(1-Methyl-pyrrolidin-2-yl)-1-oct-3 -enyl 
pyridinium bromide hydrobromide salt (NONB -3 c) 
3a. cis-1-Bromo-oct-3-ene 
To a solution of cis-oct-3-en-1-ol (1.00 g, 7.81 mmol) in 
DMF (18 mL) Was added triphenylphosphine (2.28 g, 8.69 
mmol). The solution Was cooled to 00 C. and NBS (1.50 g, 
8.43 mmol) Was added in portions. After stirring for 30 min 
at room temperature, the reaction Was quenched With metha 
nol (1 mL). The solution Was diluted With ether (100 mL), 
Washed With Water, saturated aqueous NaHCO3 and brine 
successively. The organic layer Was dried and concentrated. 
The residue Was puri?ed by ?ash chromatography on silica 
gel, eluting With hexane to afford cis-1-bromo-oct-3-ene 
(1.36 g, 91%) as a colorless oil: 1H NMR (300 MHZ, CDCl3) 
6 5.53 (1H, m), 5.35 (1H, m), 3.36 (2H, t, J:7.2 HZ), 2.60 
(2H, m), 2.04 (2H, m), 1.33 (4H, m), 0.89 (3H, t, 1:72 HZ); 
3C NMR (75 MHZ, CDCl3) 6 133.27, 125.84, 32.93, 31.97, 
31.12, 27.43, 22.64, 14.30. 
3b. (S)-cis-3-(1-Methyl-pyrrolidin-2-yl)-1-oct-3-enyl-pyri 
dinium bromide hydrobromide salt (NONB-3c) 
To a stirred solution of (S)-nicotine (0.47 g, 2.9 mmol) in 
AcOH (8 ml) Was added cis-1-bromo-oct-3-ene (1.34 g, 7.00 
mmol). The mixture Was heated at re?ux for 3 days. AcOH 
Was evaporated and the residue Was recrystalliZed in ethyl 
acetate-CHCl3 to afford (S)-cis-3-(1-methyl-pyrrolidin-2 
yl)-1-oct-3-enyl-pyridinium bromide hydrobromide salt 
(NONB-3c) (0.62 g, 49%) as hygroscopic White crystals: 1H 
NMR (300 MHZ, CDCl3) 6 12.19 (1H, s), 10.71 (1H, s), 9.74 
(1H, d, 1:78 HZ), 8.74 (1H, d, 1:57 HZ), 8.16 (1H, dd, 
1:78, 5.7 HZ), 5.79 (1H, m), 5.58 (1H, m), 5.40 (1H, m), 
4.82 (2H, m), 4.01 (1H, m), 3.03 (1H, m), 2.94 (3H, d, 1:42 
HZ), 2.204290 (5H, m), 1.87 (1H, m), 1.70 (2H, m), 
1.0(L1.25 (4H, m), 0.79 (3H, t, J:7.2 HZ); 13C NMR (75 
MHZ, CDCl3) 6 146.96, 146.29, 145.29, 136.33, 134.12, 
128.37, 121.81, 67.09, 62.01, 55.92, 38.53, 31.94, 31.41, 
29.34, 26.94, 22.18, 21.72, 14.04; Anal. Calcd for 
Cl8H3OBr2N2.0.4H2O: C, 48.97; H, 7.03; N, 6.35. Found: C, 
49.00; H, 7.36; N, 6.39. 
EXAMPLE 4 
(S)-cis-1-Dec-4-enyl-3 -(1-methyl-pyrrolidin-2-yl) 
pyridinium bromide hydrobromide salt (NDNB -4c) 
4a. cis-1-Bromo-dec-4-ene 
To a solution of cis-dec-4-en-1-ol (1.00 g, 6.41 mmol) in 
DMF (15 mL) Was added triphenylphosphine (1.87 g, 7.13 
mmol). The solution Was cooled to 00 C. and NBS (1.23 g, 
6.91 mmol) Was added in portions. After stirring for 30 min 
at room temperature, the reaction Was quenched With metha 
nol (0.6 mL). The solution Was diluted With ether (60 mL), 
US 7,091,357 B2 
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Washed With Water, saturated aqueous NaHCO3 and brine 
successively. The organic layer Was dried and concentrated. 
The residue Was puri?ed by ?ash chromatography on silica 
gel, eluting With hexane to a?‘ord cis-1-bromo-dec-4-ene 
(1.23 g, 96%) as a colorless oil: 1H NMR (300 MHZ, CDCl3) 
6 5.38 (1H, m), 5.29 (1H, m), 3.39 (2H, t, 1:69 HZ), 2.17 
(2H, m), 2.03 (2H, m), 1.88 (2H, m), 1.28 (6H, m), 0.87 (3H, 
t, 1:66 HZ); 13C NMR (75 MHZ, CDCl3) 6 131.87, 127.39, 
33.65, 32.90, 31.76, 29.63, 27.51, 25.87, 22.83, 14.35. 
4b. (S)-cis-1-Dec-4-enyl-3-(1-methyl-pyrrolidin-2-yl)-pyri 
dinium bromide hydrobromide salt (NDNB-4c) 
To a stirred solution of (S)-nicotine (0.35 g, 2.2 mmol) in 
AcOH (10 ml) Was added cis-1-bromo-dec-4-ene (1.15 g, 
5.25 mmol). The mixture Was heated at re?ux for 3 days. 
AcOH Was evaporated and the residue Was recrystallized in 
ethyl acetate-CHCl3 to a?‘ord (S)-cis-1-dec-4-enyl-3-(1-me 
thyl-pyrrolidin-2-yl)-pyridinium bromide hydrobromide salt 
(NDNB-4c) (0.54 g, 54%) as hygroscopic White crystals: 1H 
NMR (300 MHZ, CDCl3) 6 11.93 (1H, s), 10.75 (1H, s), 9.78 
(1H, d, J:7.8 HZ), 8.69 (1H, d, 1:60 HZ), 8.20 (1H, dd, 
1:78, 6.0 HZ), 5.88 (1H, m), 5.49 (1H, m), 5.30 (1H, m), 
4.72 (2H, m), 4.01 (1H, m), 3.30 (1H, m), 2.97 (3H, d, 1:51 
HZ), 2.73 (1H, m), 2.1(%2.60 (7H, m), 1.96 (2H, m), 1.70 
(2H, in), 1.154140 (6H, m), 0.86 (3H, t, J:7.2 HZ); 13C 
NMR (75 MHZ, CDCl3) 6 147.41, 146.38, 144.98, 134.68, 
132.93, 128.93, 126.06, 67.20, 62.37, 56.07, 38.71, 32.00, 
31.64, 31.38, 29.34, 27.61, 23.94, 22.74, 21.91, 14.32; Anal. 
Calcd for C2OH34Br2N2.0.5H2O: C, 50.97; H, 7.49; N, 5.94. 
Found: C, 50.90; H, 7.55; N, 5.94. 
EXAMPLE 5 
(S)-3 -(1-Methyl-pyrrolidin-2-yl)-1-oct-7-enyl-pyri 
dinium bromide (N ONB-7e) 
To a stirred solution of (S)-nicotine (0.12 g, 0.71 mmol) 
in AcOH (2 ml) Was added 8-bromo-oct-1-ene (0.34 g, 1.8 
mmol). The mixture Was heated at re?ux for 3 days. AcOH 
Was evaporated and the residue Was dissolved in CHCl3. The 
mixture Was Washed With saturated aqueous NaHCO3, Water 
and brine successively and dried. Evaporation of the solvent 
folloWed by titration With ether a?‘orded 0.19 g (77%) of 
(S) -3 -(1-methyl-pyrrolidin-2-yl)-1-oct-7-enyl-pyridinium 
bromide (NONB-7e) as a broWn oil. 1H NMR (300 MHZ, 
CDCl3) 6 9.70 (1H, d, 1:60 HZ), 9.21 (1H, s), 8.41 (1H, d, 
1:81 HZ), 8.08 (1H, dd, 1:81, 6.0 HZ), 5.72 (1H, in), 
4.864510 (4H, m), 3.50 (1H, t, 1:84 HZ), 3.22 (1H, m), 
2.41 (2H, m), 2.20 (3H, s), 1.8(L2.10 (6H, m), 1.61 (1H, m), 
12041.44 (6H, m); 13C NMR (75 MHZ, CDCl3) 6 146.12, 
144.00, 143.28, 142.63, 138.22, 128.05, 114.20, 66.68, 
61.67, 56.48, 40.29, 35.67, 33.30, 31.88, 28.33, 28.27, 
25.76, 22.98; Anal. Calcd for Cl8H29BrN2.0.35HBr: C, 
56.65; H, 7.75; N, 7.34. Found: C, 56.96; H, 7.98; N, 6.95. 
EXAMPLE 6 
(S)-1-Dec-9-enyl-3-(1-methyl-pyrrolidin-2-yl)-pyri 
dinium bromide (N DNB - 9e) 
6a. 10-Bromo-dec-1-ene 
To a solution of dec-9-en-1-ol (1.22 g, 7.82 mmol) in 
DMF (18 mL) Was added triphenylphosphine (2.30 g, 8.77 
mmol). The solution Was cooled to 00 C. and NBS (1.52 g, 
8.54 mmol) Was added in portions. After stirring for 30 min 
at room temperature, the reaction Was quenched With metha 
nol (0.8 mL). The solution Was diluted With ether (80 mL), 
Washed With Water, saturated aqueous NaHCO3 and brine 
successively. The organic layer Was dried and concentrated. 
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The residue Was puri?ed by ?ash chromatography on silica 
gel, eluting With hexane to a?‘ord 10-bromo-dec-1-ene (1.38 
g, 81%) as a colorless oil: 1H NMR (300 MHZ, CDCl3) 6 
5.80 (1H, m), 4.94 (2H, m), 3.38 (2H, t, 1:69 HZ), 2.02 (2H, 
m), 1.83 (2H, m), 1.2(L1.55 (10H, m); 13C NMR (75 MHZ, 
CDCl3)6139.17, 114.30, 34.29, 34.02, 33.06, 29.53, 29.25, 
29.12, 28.96, 28.40. 
6b. (S)-1-Dec-9-enyl-3 -(1-methyl-pyrrolidin-2-yl)-pyri 
dinium bromide (N DNB-9e) 
To a stirred solution of (S)-nicotine (0.52 g, 3.2 mmol) in 
AcOH (10 ml) Was added 10-bromo-dec-1-ene (1.66 g, 7.58 
mmol). The mixture Was heated at re?ux for 3 days. AcOH 
Was evaporated and the residue Was dissolved in CHCl3. The 
mixture Was Washed With saturated aqueous NaHCO3, Water 
and brine successively and dried. Evaporation of the solvent 
folloWed by titration With ether a?‘orded 0.74 g (61%) of 
(S)-1-dec-9-enyl-3-(1-methyl-pyrrolidin-2-yl)-pyridinium 
bromide (NDNB-9e) as a broWn oil. 1H NMR (300 MHZ, 
CDCl3) 6 9.65 (1H, d, 1:51 HZ), 9.14 (1H, s), 8.41(1H, d, 
1:81 HZ), 8.09 (1H, dd, 1:81, 5.1 HZ), 5.75 (1H, in), 
4.884510 (4H, m), 3.54 (1H, t, 1:81 HZ), 3.23 (1H, m), 
2.45 (2H, m), 2.22 (3H, s), 1.7(L2.10 (6H, m), 1.61 (1H, m), 
1.1(L1.40 (10H, m); 13C NMR (75 MHZ, CDCl3) 6 146.46, 
144.39, 143.74, 142.97, 139.07, 128.50, 114.33, 67.17, 
62.25, 56.92, 40.74, 36.11, 33.93, 32.35, 29.42, 29.24, 
29.15, 29.03, 26.35, 23.41. 
EXAMPLE 7 
(S)-3 -(1-Methyl-pyrrolidin-2-yl)-1-undec-10-enyl 
pyridinium bromide (NUNB-10e) 
7a. Undec-10-en-1-ol 
A mixture of undec-10-yn-1 -ol (0.84 g, 5.0 mmol), quino 
line (0.13 ml), Lindlar’s catalyst (100 mg, 17% W/W) and 
EtOH (20 mL) Was hydrogenated in a Parr apparatus at 50 
psi of H2 for 1 h. The mixture Was ?ltered through Celite, 
and the ?ltrate Was concentrated in vacuo to dryness to give 
undec-10-en-1-ol (0.86 g, 100%) as a colorless oil, Which 
Was used in the next step Without further puri?cation: 1H 
NMR (300 MHZ, CDCl3) 6 5.78 (1H, m), 4.92 (2H, m), 3.61 
(2H, t, 1:66 HZ), 2.01 (2H, m), 1.53 (3H, in), 1.214140 
(12H, m); 13C NMR (75 MHZ, CDCl3) 6 139.43, 114.31, 
63.24, 34.00, 32.98, 29.74, 29.61, 29.31, 29.11, 25.92. 
7b. 11-Bromo-undec-1-ene 
To a solution of undec-10-en-1-ol (0.86 g, 5.0 mmol) in 
DMF (15 mL) Was added triphenylphosphine (1.46 g, 5.6 
mmol). The solution Was cooled to 00 C. and NBS (0.96 g, 
5.4 mmol) Was added in portions. After stirring for 30 min 
at room temperature, the reaction Was quenched With metha 
nol (0.5 mL). The solution Was diluted With ether (80 mL), 
Washed With Water, saturated aqueous NaHCO3 and brine 
successively. The organic layer Was dried and concentrated. 
The residue Was puri?ed by ?ash chromatography on silica 
gel, eluting With hexane to a?‘ord 11-bromo-undec-1-ene 
(0.96 g, 82%) as a colorless oil: 1H NMR (300 MHZ, CDCl3) 
6 5.79 (1H, m), 4.93 (2H, m), 3.38 (2H, t, 1:69 HZ), 2.02 
(2H, m), 1.83 (2H, in), 1.204155 (12H, m); 13C NMR (75 
MHZ, CDCl3) 6 139.36, 114.33, 34.27, 33.99, 33.01, 29.57>< 
2, 29.27, 29.09, 28.94, 28.35. 
7c. (S)-3-(1-Methyl-pyrrolidin-2-yl)-1-undec-10-enyl-pyri 
dinium bromide (NUNB-10e) 
To a stirred solution of (S)-nicotine (0.14 g, 0.86 mmol) 
in AcOH (4 ml) Was added 11-bromo-undec-1-ene (0.50 g, 
2.1 mmol). The mixture Was heated at re?ux for 3 days. 
AcOH Was evaporated and the residue Was dissolved in 
CHCl3. The mixture Was Washed With saturated aqueous 
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NaHCO3, Water and brine successively and dried. Evapora 
tion of the solvent followed by titration With ether a?forded 
0.22 g (67%) of (S)-3-(1-methyl-pyrrolidin-2-yl)-1-undec 
10-enyl-pyridinium bromide (NUNB-10e) as a broWn oil. 
1H NMR (300 MZ, CDCl3) 6 9.61 (1H, d, J:5.7 HZ), 9.22 
(1H, s), 8.40 (1H, d, 1:81 HZ), 8.08 (1H, dd, 1:81, 6.0 HZ), 
5.77 (1H, m), 48545.10 (4H, m), 3.54 (1H, t, 1:81 HZ), 
3.24 (1H, m), 2.43 (2H, m), 2.23 (3H, s), 18042.15 (6H, m), 
1.63 (1H, m), 1.104144 (12H, m); 13C NMR (75 MHZ, 
CDCl3) 6 146.43, 144.21, 143.65, 143.09, 139.05, 128.44, 
114.16, 66.97, 62.02, 56.82, 40.62, 35.99, 33.88, 32.24, 
29.44><2, 29.18><2, 28.98, 29.26, 23.33. 
EXAMLE 8 
(S)-1-(6-Cyclobutyl-hexyl)-3 -(1-methyl-pyrrolidin 
2-yl)pyridinium bromide hydrobromide salt 
(N CyNB-4) 
8a. 6-Oxo-hexanoic acid methyl ester 
A solution of e-caprolactone (11.4 g, 0.100 mol), MeOH 
(300 mL) and concentrated HZSO4 (5 mL) Was re?uxed 
overnight. The resulting mixture Was cooled to room tem 
perature and concentrated. Water Was added to the residue 
and the pH Was adjusted to 7 With solid NaHCO3. The 
aqueous layer Was extracted With ether. The combined 
organic layers Were Washed With Water, dried and concen 
trated to give 6-hydroxy-hexanoic acid methyl ester as a 
colorless oil, Which Was used in the next step Without further 
puri?cation. 
The foregoing crude product Was dissolved in CH2Cl2 
(300 mL). Sodium acetate (2.6 g, 32 mmol) and PCC (32.7 
g, 50 mmol) Was added. After being stirred at room tem 
perature for 2 h, ether (2000 mL) Was added, the reaction 
mixture Was ?ltered through Florisil, and the ?ltrate Was 
concentrated. The residue Was distilled at reduced pressure 
(80*84° C. at 0.2 mmHg) to give 6-oxo-hexanoic acid 
methyl ester (8.58 g, 60%) as a colorless oil: 1H NMR (300 
MHZ, CDCl3) 6 9.72 (1H, t, 1:15 HZ), 3.62 (3H, s), 2.43 
(2H, m), 2.29 (2H, m), 1.62 (4H, m); 13C NMR (75 MHZ, 
CDCl3) 6 201.99, 173.64, 51.73, 43.66, 33.88, 24.53, 21.69. 
8b. 6-Cyclobutylidene-hexanoic acid methyl ester 
To a stirred suspension of KOtBu (4.81 g, 42.8 mmol) in 
tert-butyl methyl ether (tBuOMe) (50 mL) Was added 
(4-bromobutyl)triphenylphosphonium bromide (10.45 g, 
21.9 mmol). The resulting mixture Was re?uxed for 15 min 
and alloWed to cool to room temperature. A solution of 
6-oxo-hexanoic acid methyl ester (3.14 g, 21.8 mmol) in 
tBuOMe (5 mL) Was added quickly and the resulting mix 
ture Was stirred overnight. Water (30 mL) Was added. The 
aqueous phase Was extracted With hexane. The combined 
organic phases Were Washed With saturated aqueous NH4Cl 
and brine and dried. Concentration and puri?cation of the 
residue by ?ash chromatography on silica gel (hexanezethyl 
acetate, 10:1) a?forded 6-cyclobutylidene-hexanoic acid 
methyl ester (1.27 g, 32%) as a colorless oil: 1H NMR (300 
MHZ, CDCl3) 6 5.00 (1H, m), 3.64 (3H, s), 2.60 (4H, m), 
2.28 (2H, t, 1:78 HZ), 1.88 (4H, m), 1.60 (2H, m), 1.32 (2H, 
m); 13C NMR (75 MHZ, CDCl3) 6 174.25, 140.29, 119.88, 
51.66, 34.23, 31.09, 29.47, 29.44, 27.75, 24.76, 17.28. 
8c. 6-Cyclobutyl-hexan-1-ol 
To a stirred solution of 6-cyclobutylidene-hexanoic acid 
methyl ester (0.60 g, 3.3 mmol) in toluene (30 mL) Was 
added DlBAL-H (8.2 mL, 1 M solution in hexane, 8.2 
mmol) dropWise at 0° C. under N2. After stirring at 0° C. for 
30 min, the reaction Was quenched by MeOH (3 mL). 
Saturated aqueous sodium potassium tartrate (20 mL) Was 
added to the reaction mixture. After stirmg for 1 h, the 
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organic layer Was separated and the aqueous phase Was 
extracted With ether. The combined organic layers Were 
Washed With Water and brine and dried. Evaporation of the 
solvent gave 6-cyclobutylidene-hexan-1-ol as a colorless oil, 
Which Was used in the next step Without further puri?cation. 
A solution of the foregoing product in MeOH (20 mL) 
Was hydrogenated With PdiC (0.12 g, 10% W/W) in a Parr 
apparatus at 50 psi of H2 overnight. The catalyst Was 
removed by ?ltration, and the ?ltrate Was evaporated under 
reduced pressure to give 6-cyclobutyl-hexan-1-ol (0.48 g, 
88%) as a colorless oil: 1H NMR (300 MHZ, CDCl3) 6 3.62 
(2H, t, 1:66 HZ), 2.22 (1H, m), 2.03 (2H, m), 1.80 (2H, m), 
1.55 (5H, m), 1.104140 (8H, m); 13C NMR (75 MHZ, 
CDCl3) 6 63.28, 37.25, 36.42, 33.05, 29.71, 28.68, 27.40, 
26.04, 18.78. 
8d. (6-Bromo-hexyl)-cyclobutane 
To a solution of 6-cyclobutyl-hexan-1-ol (0.47 g, 3.0 
mmol) in DMF (10 mL) Was added triphenylphosphine 
(0.88 g, 3.4 mmol). The solution Was cooled to 00 C. and 
NBS (0.57 g, 3.2 mmol) Was added in portions. After stirring 
for 30 min at room temperature, the reaction Was quenched 
With methanol (0.5 mL). The solution Was diluted With ether 
(60 mL), Washed With Water, saturated aqueous NaHCO3 
and brine successively. The organic layer Was dried and 
concentrated. The residue Was puri?ed by ?ash chromatog 
raphy on silica gel, eluting With hexane to afford (6-bromo 
hexyl)-cyclobutane (0.60 g, 91%) as a colorless oil: 1H 
NMR (300 MHZ, CDCl3) 6 3.40 (2H, t, 1:69 HZ), 2.23 (1H, 
m), 2.02 (2H, m), 1.82 (4H, m), 1.55 (2H, m), 1.12*1.46 
(8H, m); 13C NMR (75 MHZ, CDCl3) 6 37.19, 36.39, 34.40, 
33.11, 29.07, 28.68, 28.51, 27.26, 18.80. 
8e. (S)-1-(6-Cyclobutyl-hexyl)-3-(1—methyl-pyrrolidin-2 
yl)-pyridinium bromide hydrobromide salt (N CyNB-4) 
To a stired solution of (S)-nicotine (0.18 g, 1.1 mmol) in 
AcOH (4 ml) Was added (6-bromo-hexyl)cyclobutane (0.59 
g, 2.7 mmol). The mixture Was heated at re?ux for 3 days. 
AcOH Was evaporated and the residue Was recrystalliZed in 
ethyl acetate-CHCl3 to afford (S)-1-(6-cyclobutyl-hexyl)-3 
(1-methyl-pyrrolidin-2-yl)-pyridinium bromide hydrobro 
mide salt (NCyNB4) (0.31 g, 61%) as hygroscopic White 
crystals: 1H NMR (300 MHZ, CDCl3) 6 11.64 (1H, s), 10.42 
(1H, s), 9.54 (1H, d, 1:81 HZ), 9.06 (1H, d, 1:60 HZ), 8.27 
(1H, dd, 1:81, 6.0 HZ), 5.74 (1H, m), 4.78 (2H, m), 3.98 
(1H, m), 3.34 (1H, m), 2.96 (3H, d, 1:51 HZ), 2.73 (1H, m), 
2.44 (3H, m), 2.14 (3H, m), 1.96 (2H, m), 1.75 (2H, m), 1.51 
(2H, m), 1.33 (6H, m), 1.16 (2H, m); 13C NMR (75 MHZ, 
CDCl3) 6 147.61, 146.61, 144.67, 134.77, 128.91, 67.09, 
63.07, 56.09, 38.71, 36.99, 36.17, 32.06, 31.76, 29.20, 
28.60, 27.14, 26.53, 21.89, 18.72; Anal. Calcd for 
C2OH34Br2N2.0.1H2O: C, 51.56; H, 7.44; N, 6.01. Found: C, 
51.70; H, 7.45; N, 5.96. 
EXAMPLE 9 
(S)-1-(6-Cyclopentyl-hexyl)-3-(1-methyl-pyrrolidin 
2-yl)-pyridinium bromide hydrobromide salt 
(N CyNB-5) 
9a. 6-Cyclopentylidene-hexanoic acid methyl ester 
To a stirred suspension of cyclopentyltriphenylphospho 
nium bromide (10.0 g, 23.8 mmol) in TMF (60 mL) Was 
added dropWise n-BuLi (10.2 mL, 2.5 M solution in hex 
anes, 23.8 mmol) at 0° C. under N2. The resulting solution 
Was stirred at this temperature for 30 min and cooled to —78 
° C. A solution of 6-oxo-hexanoic acid methyl ester (3.33 g, 
23.1 mmol) in THF (6 mL) Was added quickly. The resulting 
mixture Was then alloWed to Warm to room temperature and 
stirred overnight. Water (30 mL) Was added. The aqueous 
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phase Was extracted With hexane. The combined organic 
phases Were Washed With saturated aqueous NH4Cl and 
brine and dried. Concentration and puri?cation of the resi 
due by ?ash chromatography on silica gel (hexane:ethyl 
acetate, 10:1) a?forded 6-cyclopentylidene-hexanoic acid 
methyl ester (3.15 g, 70%) as a colorless oil: 1H NMR (300 
MHZ, CDCl3) 6 5.20 (1H, m), 3.64 (3H, s), 2.29 (2H, m), 
2.16 (4H, m), 1.96 (2H, m), 1.62 (6H, m), 1.35 (2H, m); 13C 
NMR (75 MHZ, CDCl3) 6 174.26, 143.54, 119.65, 51.66, 
34.29, 33.79, 29.44, 28.86, 26.69, 26.61, 24.91. 
9b. 6-Cyclopentylidene-hexan-1-ol 
To a stirred solution of 6-cyclopentylidene-hexanoic acid 
methyl ester (2.77 g, 14.1 mmol) in toluene (130 mL) Was 
added DlBAL-H (35.3 mL, 1 M solution in hexane, 35.3 
mmol) dropWise at 0° C. under N2. After sting at 0° C. for 
30 min, the reaction Was quenched by MeOH (10 mL). 
Saturated aqueous sodium potassium tartrate (80 mL) Was 
added to the reaction mixture. After stirring for 1 h, the 
organic layer Was separated and the aqueous phase Was 
extracted With ether. The combined organic layers Were 
Washed With Water and brine and dried. Evaporation of the 
solvent gave 6-cyclopentylidene-hexan-1-ol (2.47 g, 98%) 
as a colorless oil: 1H NMR (300 MHZ, CDCl3) 6 5.24 (1H, 
m), 3.63 (2H, t, 1:66 HZ), 2.21 (4H, m), 1.97 (2H, m), 
15041.70 (6H, m), 1.34 (2H, m); 13C NMR (75 MHZ, 
CDCl3) 6 143.28, 120.08, 63.22, 33.82, 33.00, 29.81, 29.75, 
28.87, 26.72, 26.63, 25.73. 
9c. 6-Cyclopentyl-hexan-1-ol 
Asolution of 6-cyclopentylidene-hexan-1-ol (1.15 g, 6.85 
mmol) in MeOH (50 mL) Was hydrogenated With Pd4C 
(0.25 g, 10% W/W) in a Parr apparatus at 50 psi of H2 
overnight. The catalyst Was removed by ?ltration, and the 
?ltrate Was evaporated under reduced pressure to give 
6-cyclopentyl-hexan-1-ol (1.30 g, 100%) as a colorless oil: 
1H NMR (300 MHZ, CDCl3) 6 3.63 (2H, t, 1:66 HZ), 
1.424164 (6H, m), 12041.40 (8H, m), 1.04(2H, m); 13C 
NMR (75 MHZ, CDCl3) 6 63.28, 40.41, 36.43, 33.06, 33.00, 
29.98, 29.04, 26.05, 25.47. 
9d. (6-Bromo-hexyl)-cyclopentane 
To a solution of 6-cyclopentyl-hexan-1-ol (1.20 g, 7.06 
mmol) in DMF (20 mL) Was added triphenylphosphine 
(2.08 g, 7.93 mmol). The solution Was cooled to 00 C. and 
NBS (1.36 g, 7.64 mmol) Was added in portions. After 
stirring for 30 min at room temperature, the reaction Was 
quenched With methanol (1 mL). The solution Was diluted 
With ether (100 mL), Washed With Water, saturated aqueous 
NaHCO3 and brine successively. The organic layer Was 
dried and concentrated. The residue Was puri?ed by ?ash 
chromatography on silica gel, eluting With hexane to afford 
(6-bromo-hexyl)-cyclopentane (1.55 g, 94%) as a colorless 
oil: 1H NMR (300 MHZ, CDCl3) 6 3.40 (2H, t, J:6.9 HZ), 
1.85 (2H, m), 1.73 (3H, m), 13841.64 (6H, in), 1.244138 
(6H, m), 1.04 (2H, m); 13C NMR (75 MHZ, CDCl3) 6 40.38, 
36.37, 34.35, 33.12, 32.99, 29.33, 28.87, 28.49, 25.46. 
9e. (S)-1-(6-Cyclopentyl-hexyl)-3-(1—methyl-pyrrolidin-2 
yl)-pyridinium bromide hydrobromide salt (NCyNB-5) 
To a stirred solution of (S)-nicotine (0.43 g, 2.6 mmol) in 
AcOH (10 ml) Was added (6-bromo-hexyl)-cyclopentane 
(1.50 g, 6.44 mmol). The mixture Was heated at re?ux for 3 
days. AcOH Was evaporated and the residue Was recrystal 
liZed in ethyl acetate-CHCl3 to afford (S)-1-(6-cyclopentyl 
hexyl) -3 -( 1 —methyl -pyrrolidin-2 -yl)-pyridinium bromide 
hydrobromide salt (NCyNB-5) (0.68 g, 54%) as hygroscopic 
White crystals: 1H NMR (300 MHZ, CDCl3) 6 11.74 (1H, s), 
10.52 (1H, s), 9.62 (1H, d, 1:84 HZ), 8.99 (1H, d, 1:60 HZ), 
8.29 (1H, dd, 1:78, 6.3 HZ), 5.80 (1H, m), 4.78 (2H, m), 
4.01 (1H, m), 3.35 (1H, m), 2.98 (3H, d, 1:51 HZ), 2.76 
(1H, m), 2.45 (3H, m), 2.15 (2H, m), 1.70 (3H, m), 
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1.154160 (12H, m), 1.02 (2H, m); 13c NMR (75 MHZ, 
CDC13) 6 147.78, 146.78, 144.41, 134.94, 128.90, 67.03, 
63.14, 56.10, 40.26, 38.72, 36.23, 32.96, 32.11, 31.82, 
29.48, 28.77, 26.55, 25.43, 21.89; Anal. Calcd for 
C2lH36Br2N2.0.2H2O: c, 52.55, H, 7.64; N, 5.84. Found: c, 
52.41, H, 7.56; N, 5.78. 
EXAMPLE 10 
(S)-1-(6-Cyclohexyl-hexyl)-3 -(1-methyl-pyrrolidin 
2-yl)-pyridinium bromide hydrobromide salt 
(N CyNB-6) 
10a. 6-Cyclohexylidene-hexanoic acid methyl ester 
To a stirred suspension of cyclohexyltriphenylphospho 
nium bromide (8.40 g, 19.8 mmol) in THF (50 mL) Was 
added dropWise n-BuLi (8.70 mL, 2.5 M solution in hex 
anes, 21.8 mmol) at 0° C. under N2. The resulting solution 
Was stired at this temperature for 30 min and cooled to —78° 
C. A solution of 6-oxo-hexanoic acid methyl ester (2.84 g, 
19.7 mmol) in THF (6 mL) Was added quickly. The resulting 
mixture Was then alloWed to Warm to room temperature and 
stirred overnight. Water (30 mL) Was added. The aqueous 
phase Was extracted With hexane. The combined organic 
phases Were Washed With saturated aqueous NH4Cl and 
brine and dried. Concentration and puri?cation of the resi 
due by ?ash chromatography on silica gel (hexane:ethyl 
acetate, 10:1) afforded 6-cyclohexylidene-hexanoic acid 
methyl ester (2.02 g, 49%) as a colorless oil: 1H NMR (300 
MHZ, CDCl3) 6 5.03 (1H, t, 1:66 HZ), 3.64 (3H, s), 2.29 
(2H, m), 2.03 (6H, m), 1.61 (2H, in), 1.414154 (6H, m), 
1.34 (2H, m); 13C NMR (75 MHZ, CDCl3) 6 174.26, 140.05, 
120.82, 51.66, 37.40, 34.26, 29.89, 28.93, 28.08, 27.20, 
26.89, 24.79. 
10b. 6-Cyclohexylidene-hexan- 1 -ol 
To a stired solution of 6-cyclohexylidene-hexanoic acid 
methyl ester (1.28 g, 6.10 mmol) in toluene (60 mL) Was 
added DlBAL-H (15.3 mL, 1 M solution in hexane, 15.3 
mmol) dropWise at 0° C. under N2. After stirring at 0° C. for 
30 min, the reaction Was quenched by MeOH (5 mL). 
Saturated aqueous sodium potassium tartrate (40 mL) Was 
added to the reaction mixture. After string for 1 h, the 
organic layer Was separated and the aqueous phase Was 
extracted With ether. The combined organic layers Were 
Washed With Water and brine and dried. Evaporation of the 
solvent gave 6-cyclohexylidene-hexan-1-ol (1.12 g, 100%) 
as a colorless oil: 1H NMR (300 MHZ, CDCl3) 6 5.05 (1H, 
m), 3.62 (2H, t, 1:66 HZ), 2.05 (6H, in), 1.424164 (8H, m), 
1.34 (2H, m); 13C NMR (75 MHZ, CDCl3) 6 139.78, 121.25, 
63.22, 37.43, 32.96, 30.22, 28.96, 28.11, 27.23, 25.58. 
10c. 6-Cyclohexyl-hexan-1-ol 
A solution of 6-cyclohexylidene-hexan-1-ol (1.05 g, 5.77 
mmol) in MEOH (40 mL) Was hydrogenated With Pd4C 
(0.23 g, 10% W/W) in a Parr apparatus at 50 psi of H2 
overnight. The catalyst Was removed by ?ltration, and the 
?ltrate Was evaporated under reduced pressure to give 
6-cyclohexyl-hexan-1-ol (1.02 g, 96%) as a colorless oil: 1H 
NMR (300 MHZ, CDCl3) 6 3.63 (2H, t, 1:66 HZ), 1.464180 
(7H, m), 10441.44 (12H, m), 0.86 (2H, m); 13C NMR (75 
MHZ, CDCl3) 6 63.33, 37.92, 37.74, 33.72, 33.08, 30.04, 
27.10, 27.04, 26.73, 26.05. 
10d. (6—Bromo-hexyl)-cyclohexane 
To a solution of 6-cyclohexyl-hexan-1-ol (0.98 g, 5.3 
mmol) in DMF (15 mL) Was added triphenylphosphine 
(1.56 g, 5.9 mmol). The solution Was cooled to 0° C. and 
NBS (1.02 g, 5.7 mmol) Was added in portions. After stirring 
for 30 min at room temperature, the reaction Was quenched 
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With methanol (0.6 mL). The solution Was diluted With ether 
(80 mL), Washed With Water, saturated aqueous NaHCO3 
and brine successively. The organic layer Was dried and 
concentrated. The residue Was puri?ed by ?ash chromatog 
raphy on silica gel, eluting With hexane to a?‘ord (6-bromo 
hexyl)-cyclohexane (1.16 g, 89%) as a colorless oil: 1H 
NMR (300 MHZ, CDCl3) 6 3.41 (2H, t, J:7.2 HZ), 1.85 (2H, 
m), 1.66 (5H, m), 1.42 (2H, m), 1.084136 (10H, m), 0.88 
(2H, m); 13C NMR (75 MHZ, CDCl3) 6 37.91, 37.68, 34.37, 
33.72, 33.14, 29.39, 28.51, 27.04, 26.96, 26.73. 
10e. (S)-1-(6-Cyclohexyl-hexyl)-3 -(1-methyl-pyrrolidin-2 
yl)-pyridinium bromide hydrobromide salt (NCyNB-6) 
To a stirred solution of (S)-nicotine (0.31 g, 1.9 mmol) in 
AcOH (8 ml) Was added (6-bromo-hexyl)-cyclohexane 
(1.15 g, 4.65 mmol). The mixture Was heated at re?ux for 3 
days. AcOH Was evaporated and the residue Was recrystal 
liZed in ethyl acetate-CHCl3 to a?‘ord (S)-1-(6-cyclohexyl 
hexyl) -3 -( 1 -methyl -pyrrolidin-2 -yl)-pyridinium bromide 
hydrobromide salt (NCyNB-6) (0.59 g, 63%) as hygroscopic 
White crystals: 1H NMR (300 MHZ, CDCl3) 6 11.71 (1H, s), 
10.44 (1H, s), 9.58 (1H, d, 1:81 HZ), 9.04 (1H, d, 1:60 HZ), 
8.29 (1H, dd, 1:78, 6.0 HZ), 5.75 (1H, m), 4.78 (2H, m), 
4.02 (1H, m), 3.37 (1H, m), 2.98 (3H, d, 1:48 HZ), 2.75 
(1H, m), 2.48 (3H, m), 2.13 (2H, m), 1.65 (5H, m), 
10541.45 (12H, m), 0.83 (2H, m), 13C NMR (75 MHZ, 
CDCl3) 6 147.66, 146.65, 144.57, 134.85, 128.93, 67.09, 
63.11, 56.09, 38.71, 37.77, 37.52, 33.61, 32.09, 31.80, 
29.53, 26.92, 26.84, 26.63, 26.54, 21.89; Anal. Calcd for 
C22H38Br2N2.0.3H2O: C, 53.30; H, 7.85; N, 5.65. Found: C, 
53.35; H, 7.74; N, 5.70. 
EXAMPLE 11 
(S)-3 -(1-Methyl-pyrrolidin-2-yl)-1-oct-3 -ynyl-pyri 
dinium bromide (N ONB-3y) 
11a. 1-Bromo-oct-3-yne 
To a solution of oct-3-yn-1-ol (1.26 g, 10.0 mmol) in 
DMF (25 mL) Was added triphenylphosphine (2.92 g, 11.2 
mmol). The solution Was cooled to 00 C. and NBS (1.92 g, 
10.8 mmol) Was added in portions. After stirring for 30 min 
at room temperature, the reaction Was quenched With metha 
nol (1 mL). The solution Was diluted With ether (150 mL), 
Washed With Water, saturated aqueous NaHCO3 and brine 
successively. The organic layer Was dried and concentrated. 
The residue Was puri?ed by ?ash chromatography on silica 
gel, eluting With hexane to a?‘ord 1-bromo-oct-3-yne (1.35 
g, 71%) as a colorless oil: 1H NMR (300 MHZ, CDCl3) 6 
3.40 (2H, d, J:7.2 HZ), 2.78 (2H, m), 2.15 (2H, m), 1.22 
(4H, m), 0.88 (3H, t, 1:69 HZ); 13C NMR (75 MHZ, CDCl3) 
6 82.83, 77.05, 31.18, 30.63, 23.68, 22.20, 18.67, 13.89. 
11b. (S)-3-(1-Methyl-pyrrolidin-2-yl)-1-oct-3-ynyl-pyri 
dinium bromide (N ONB-3y) 
To a stirred solution of (S)-nicotine (0.41 g, 2.5 mmol) in 
AcOH (10 ml) Was added 1-bromo-oct-3-yne (1.16 g, 6.14 
mmol). The mixture Was heated at re?ux for 3 days. AcOH 
Was evaporated and the residue Was dissolved in CHCl3. The 
mixture Was Washed With saturated aqueous NaHCO3, Water 
and brine successively and dried. Evaporation of the solvent 
folloWed by titration With ether a?‘orded 0.50 g (56%) of 
(S) -3 -(1-methyl-pyrrolidin-2-yl)-1-oct-3 -ynyl-pyridinium 
bromide (NONB-3y) as a broWn oil. 1H NMR (300 MHZ, 
CDCl3) 6 9.74 (1H, d, 1:51 HZ), 9.15 (1H, s), 8.43 (1H, d, 
1:78 HZ), 8.04 (1H, dd, 1:78, 5.1 HZ), 5.13 (2H, m), 3.51 
(1H, t, 1:78 HZ), 3.23 (1H, m), 3.00 (2H, m), 2.42 (2H, m), 
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2.22 (3H, s), 2.01 (2H, m), 1.89 (2H, m), 1.64 (2H, m), 1.28 
(4H, m), 0.82 (3H, 1, 1:72 HZ); 13C NMR (75 MHZ, CDC13) 
6 145.97, 144.38, 144.10, 143.57, 128.00, 86.12, 74.07, 
67.30, 60.72, 56.92, 40.74, 36.11, 30.94, 23.14, 22.50, 
22.16, 18.54, 13.80; Anal. Calcd for Cl8H27BrN2.0.5H2O: 
c, 60.00; H, 7.83; N, 7.77. Found: c, 60.15; H, 7.92, N, 
6.92. 
EXAMPLE 12 
(S)-1-Dec-3 -ynyl-3-(1-methyl-pyrrolidin-2-yl)-pyri 
dinium bromide (NDNB -3y) 
12a. 1-bromo-dec-3-yne 
To a solution of dec-3-yn-1-ol (1.54 g, 10.0 mmol) in 
DMF (25 mL) Was added triphenylphosphine (2.92 g, 11.2 
mmol). The solution Was cooled to 00 C. and NBS (1.92 g, 
10.8 mmol) Was added in portions. After stirring for 30 min 
at room temperature, the reaction Was quenched With metha 
nol (1 mL). The solution Was diluted With ether (150 mL), 
Washed With Water, saturated aqueous NaHCO3 and brine 
successively. The organic layer Was dried and concentrated. 
The residue Was puri?ed by ?ash chromatography on silica 
gel, eluting With hexane to a?‘ord 1-bromo-dec-3-yne (1.57 
g, 72%) as a colorless oil: 1H NMR (300 MHZ, CDCl3) 6 
3.40 (2H, d, J:7.2 HZ), 2.70 (2H, m), 2.14 (2H, m), 
1.2(L1.55 (8H, m), 0.88 (3H, t, 1:69 HZ); 13C NMR (75 
MHZ, CDCl3) 6 82.89, 77.05, 31.62, 30.68, 29.06, 28.78, 
23.65, 22.86, 18.99, 13.38. 
12b. (S)-1-Dec-3 -ynyl-3 -(1-methyl-pyrrolidin-2-yl)-pyri 
dinium bromide Q\IDNB-3y) 
To a stirred solution of (S)-nicotine (0.46 g, 2.8 mmol) in 
AcOH (15 ml) Was added 1-bromo-dec-3-yne (1.50 g, 6.91 
mmol). The mixture Was heated at re?ux for 3 days. AcOH 
Was evaporated and the residue Was dissolved in CHCl3. The 
mixture Was Washed With saturated aqueous NaHCO3, Water 
and brine successively and dried. Evaporation of the solvent 
folloWed by titration With ether a?‘orded 0.55 g (51%) of 
(S)-1-dec-3-ynyl-3 -(1-methyl-pyrrolidin-2-yl)-pyridinium 
bromide (NDNB-3y) as a broWn oil. 1H NMR (300 MHZ, 
CDCl3) 6 9.77 (1H, d, 1:57 HZ), 9.14 (1H, s), 8.43 (1H, d, 
1:81 HZ), 8.04 (1H, dd, 1:81, 5.7 HZ), 5.16 (2H, m), 3.52 
(1H, t, 1:81 HZ), 3.27 (1H, m), 3.03 (2H, m), 2.47 (2H, m), 
2.26 (3H, s), 18542.10 (4H, m), 1.70 (1H, m), 1.15*1.45 
(8H, m), 0.86 (3H, t, J:7.2 HZ); 13C NMR (75 MHZ, CDCl3) 
6 145.91, 144.24, 144.12, 143.57, 128.02, 86.16, 73.98, 
67.24, 60.66, 56.87, 40.70, 36.05, 31.44, 28.86, 28.75, 
23.36, 22.71, 22.45, 18.82, 14.27; Anal. Calcd for 
C2OH31BrN2.0.7H2O: C, 61.28; H, 8.33; N, 7.15. Found: C, 
61.14; H, 8.21; N, 7.14. 
EXAMPLE 13 
(S)-1-(7-Methyl-oct-6-enyl)-3-(1—methyl-pyrrolidin 
2-yl)-pyridinium bromide hydrobromide (NONB 
6e7M) 
13a. 7-Methyl-oct-6-enoic acid methyl ester 
To a stirred suspension of isopropyltriphenylphospho 
nium bromide (10.9 g, 28.3 mmol) in THF (60 mL) Was 
added dropWise n-BuLi (12.0 mL, 2.5 M solution in hex 
anes, 30.0 mmol) at 0° C. under N2. The resulting solution 
Was stirred at this temperature for 30 min and cooled to —78° 
C. A solution of 6-oxo-hexanoic acid methyl ester (3.95 g, 
19.7 mmol) in THF (10 mL) Was added quickly. The 
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resulting mixture Was then allowed to Warm to room tem 
perature and stirred overnight. Water (30 mL) Was added. 
The aqueous phase Was extracted With hexane. The com 
bined organic phases Were Washed With saturated aqueous 
NH4Cl and brine and dried. Concentration and puri?cation 
of the residue by ?ash chromatography on silicagel (hexane: 
ethyl acetate, 10:1) a?forded 7-methyl-oct-6-enoic acid 
methyl ester (3.39 g, 72%) as a colorless oil: 1H NMR (300 
MHZ, CDCl3) 6 5.08 (1H, m), 3.64 (3H, s), 2.29 (2H, t, J:7.2 
HZ), 1.97 (2H, m), 1.66 (3H, s), 1.62 (2H, m), 1.58 (3H, s), 
1.36 (2H, m); 13C NMR (75 MHZ, CDCl3) 6 174.26, 140.05, 
131.80, 124.27, 51.67, 34.29, 29.60, 27.89, 25.97, 24.87, 
17.94. 
13b. 7-Methyl-oct-6-en-1-ol 
To a stirred solution of 7-methyl-oct-6-enoic acid methyl 
ester (3.29 g, 19.4 mmol) in toluene (180 mL) Was added 
DlBAL-H (48.5 mL, 1 M solution in hexane, 48.5 mmol) 
dropWise at 0° C. under N2. After stirring at 0° C. for 30 min, 
the reaction Was quenched by MeOH (12 mL). Saturated 
aqueous sodium potassium tartrate (120 mL) Was added to 
the reaction mixture. After stirring for 1 h, the organic layer 
Was separated and the aqueous phase Was extracted With 
ether. The combined organic layers Were Washed With Water 
and brine and dried. Evaporation of the solvent gave 7-me 
thyl-oct-6-en-1-ol (2.70 g, 98%) as a colorless oil: 1H NMR 
(300 MHZ, CDCl3) 6 5.11 (1H, m), 3.63 (2H, m), 1.99 (2H, 
m), 1.68 (3H, s), 1.59 (3H, s), 1.53 (2H, m), 12541.45 (4H, 
m); 13C NMR (75 MHZ, CDCl3) 6 131.52, 124.69, 63.25, 
33.00, 29.95, 28.25, 26.02, 25.69, 17.98. 
13c. 8-Bromo-2-methyl-oct-2-ene 
To a solution of 7-methyl-oct-6-en-1-ol (1.00 g, 7.04 
mmol) in DMF (18 mL) Was added triphenylphosphine 
(2.06 g, 7.85 mmol). The solution Was cooled to 00 C. and 
NBS (1.35 g, 7.58 mmol) Was added in portions. After 
stirring for 30 min at room temperature, the reaction Was 
quenched With methanol (1 mL). The solution Was diluted 
With ether (100 mL), Washed With Water, saturated aqueous 
NaHCO3 and brine successively. The organic layer Was 
dried and concentrated. The residue Was puri?ed by ?ash 
chromatography on silica gel, eluting With hexane to afford 
8-bromo-2-methyl-oct-2-ene (1.11 g, 77%) as a colorless 
oil: 1H NMR (300 MHZ, CDCl3) 6 5.10 (1H, m), 3.40 (2H, 
t, 1:69 HZ), 1.98 (2H, m), 1.86 (2H, m), 1.68 (3H, d, 1:09 
HZ), 1.60 (3H, d, 1:03 HZ), 1.42 (2H, m), 1.41 (4H, m); 13C 
NMR (75 MHZ, CDCl3) 6 132.08, 124.81, 34.59, 33.44, 
29.64, 28.49, 28.44, 26.36, 18.35. 
13d. (S)-1-(7-Methyl-oct-6-enyl)-3-(1-methyl-pyrrolidin-2 
yl)-pyridinium bromide hydrobromide (NONB-6e7M) 
To a stired solution of (S)-nicotine (0.33 g, 2.0 mmol) in 
AcOH (10 ml) Was added 8-bromo-2-methyl-oct-2-ene 
(1.05 g, 5.12 mmol). The mixture Was heated at re?ux for 3 
days. AcOH Was evaporated and the residue Was recrystal 
liZed in ethyl acetate-CHCl3 to (S)-1-(7-methyl-oct-6-enyl) 
3 -( 1 -methyl-pyrrolidin-2 -yl)-pyridinium bromide hydrobro 
mide (NONB-6e7M) (0.58 g, 63%) as hygroscopic White 
crystals: 1H NMR (300 MHZ, CDCl3) 6 11.61 (1H, s), 10.38 
(1H, s), 9.52 (1H, d, 1:81 HZ), 9.17 (1H, d, 1:60 HZ), 8.31 
(1H, dd, 1:81, 6.0 HZ), 5.75 (1H, m), 5.03(1H, m), 4.81 
(2H, m), 4.00 (1H, m), 3.37 (1H, m), 2.98 (3H, s), 18042.25 
(4H, m), 1.64 (3H, s), 1.55 (3H, s), 1.39 (4H, m); 13C NMR 
(75 MHZ, CDCl3) 6 147.49, 146.49, 144.86, 134.65, 132.20, 
128.91, 123.74, 67.14, 62.95, 56.09, 38.69, 32.02, 31.67, 
29.34, 27.87, 26.04, 21.91, 18.05; Anal. Calcd for 
Cl9H32Br2N2.0.7H2O: C, 49.52; H, 7.28; N, 6.08. Found: C, 
49.44; H, 7.18; N, 6.07. 
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EXAMPLE 14 
(S)-1-(7-Methyl-octyl)-3 -(1-methyl-pyrrolidin-2-yl) 
pyridinium bromide hydrobromide salt (N ONB 
7M) 
14a. 7-Methyl-octan-1-ol 
A solution of7-methyl-oct-6-en-1-ol (1.42 g, 10.0 mmol) 
in MeOH (70 mL) Was hydrogenated With PdiC (0.40 g, 
10% W/W) in a Parr apparatus at 50 psi of H2 overnight. The 
catalyst Was removed by ?ltration, and the ?ltrate Was 
evaporated under reduced pressure to give 7-methyl-octan 
1-ol (1.38 g, 96%) as a colorless oil: 1H NMR (300 MHZ, 
CDCl3) 6 3.64 (2H, t, 1:66 HZ), 1.54 (3H, m), 1.104144 
(8H, m), 0.88 (3H, s), 0.85 (3H, s); 13C NMR (75 MHZ, 
CDCl3) 6 63.28, 39.21, 33.06, 29.98, 28.24, 27.64, 26.06, 
22.94. 
14b. 1-Bromo -7 -methyl-octane 
To a solution of 7-methyl-octan-1-ol (1.20 g, 8.33 mmol) 
in DMF (20 mL) Was added triphenylphosphine (2.43 g, 
9.26 mmol). The solution Was cooled to 0° C. and NBS (1.60 
g, 8.99 mmol) Was added in portions. After stirring for 30 
min at room temperature, the reaction Was quenched With 
methanol (1 mL). The solution Was diluted With ether (100 
mL), Washed With Water, saturated aqueous NaHCO3 and 
brine successively. The organic layer Was dried and concen 
trated. The residue Was puri?ed by ?ash chromatography on 
silica gel, eluting With hexane to afford 1-bromo-7-methyl 
octane (1.28 g, 74%) as a colorless oil: 1H NMR (300 MHZ, 
CDCl3) 6 3.41 (2H, t, 1:66 HZ), 1.85 (2H, m), 1.52 (1H, m), 
1.42 (2H, m), 1.28 (4H, m), 1.17 (2H, m), 0.87 (3H, s), 0.85 
(3H, s); 13C NMR (75 MHZ, CDCl3) 6 39.16, 34.34, 33.14, 
29.34, 28.52, 28.24, 27.51, 22.94. 
14c. (S)-1-(7-Methyl-octyl)-3-(1-methyl-pyrrolidin-2-yl) 
pyridinium bromide hydrobromide salt (N ONB-7M) 
To a stirred solution of (S)-nicotine (0.37 g, 2.3 mmol) in 
AcOH (10 ml) Was added 1-bromo-7-methyl-octane (1.20 g, 
5.80 mmol). The mixture Was heated at re?ux for 3 days. 
AcOH Was evaporated and the residue Was recrystalliZed in 
ethyl acetate-CHCl3 to (S)-1-(7-methyl-octyl)-3-(1-methyl 
pyrrolidin-2-yl)-pyridinium bromide hydrobromide salt 
(NONB-7M) (0.60 g, 58%) as hygroscopic White crystals: 
1H NMR (300 MHZ, CDCl3) 6 11.85 (1H, s), 10.61 (1H, s), 
9.68 (1H, d, 1:84 HZ), 8.83 (1H, d, 1:60 HZ), 8.24 (1H, dd, 
1:81, 6.3 HZ), 5.80 (1H, m), 4.75 (2H, m), 4.01 (1H, m), 
3.32 (1H, m), 2.96 (3H, d, 1:48 HZ), 2.74 (1H, m), 
2.3(%2.60 (3H, m), 2.11 (2H, m), 1.054155 (9H, m), 0.82 
(6H, d, 1:66 HZ); 13C NMR (75 MHZ, CDCl3) 6 147.64, 
146.61, 144.97, 134.71, 129.09, 67.21, 63.13, 56.16, 38.97, 
32.15, 31.82, 29.48, 28.10, 27.36, 26.55, 22.86, 21.97; Anal. 
Calcd for Cl9H34Br2N2.0.3H2O: C, 50.09; H, 7.63; N, 6.15. 
Found: C, 50.08; H, 7.64; N, 6.13. 
EXAMPLE 15 
(S)-1-[2-(2-Ethoxy-ethoxy)-ethyl]-3-(1-methyl-pyr 
rolidin-2 -yl) -pyridinium bromide (NONB -3060) 
To a stirred solution of (S)-nicotine (0.67 g, 4.1 mmol) in 
AcOH (20 ml) Was added 1-bromo-2-(2-ethoxy-ethoxy) 
ethane (1.97 g, 10.0 mmol). The mixture Was heated at re?ux 
for 3 days. AcOH Was evaporated and the residue Was 
dissolved in CHCl3. The mixture Was Washed With saturated 
aqueous NaHCO3, Water and brine successively and dried. 
Evaporation of the solvent folloWed by titration With ether 
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a?forded 0.56 g (38%) of (S)-1-[2-(2-ethoxy-ethoxy)-ethyl] 
3 -(1 -methyl-pyrrolidin-2 -yl)-pyridinium bromide (NONB 
3060) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 6 9.65 
(1H, d, 1:60 HZ), 9.26 (1H, s), 8.44 (1H, d, 1:78 HZ), 7.99 
(1H, dd, 1:78, 6.0 HZ), 5.27 (2H, t, 1:48 HZ), 4.06 (2H, t, 
1:48 HZ), 3.64 (2H, m), 3.414360 (5H, m), 3.26 (1H, m), 
2.43 (2H, m), 2.25 (3H, s), 1.91 (2H, m), 1.60 (1H, m), 1.16 
(3H, t, 1:69 HZ); 13C NMR (75 MHZ, CDCl3) 6 145.87, 
144.40><2, 144.02, 127.85, 70.83, 69.72, 69.57, 67.17, 66.77, 
61.41, 56.91, 40.67, 36.02, 23.41, 15.47; Anal. Calcd for 
Cl6H27BrN2.0.5H2O: C, 52.18; H, 7.66; N, 7.61. Found: C, 
52.22; H, 7.68; N, 7.50. 
EXAMLE 16 
(S)-1-(9-Acetoxy-nonyl)-3 -(1-methyl-pyrrolidin-2 
yl) -pyridinium bromide (NANNB) 
To a stirred solution of (S)-nicotine (2.0 ml, 12.2 mmol) 
in AcOH (25 ml) 1,9 dibromononane (1.28 g, 6.2 mmol) Was 
added. The mixture Was re?uxed for 3 days. After evapo 
ration of the AcOH, the resulting residue Was basi?ed using 
saturated aqueous NaHCO3. The resulting aqueous solution 
Was extracted three times With ethyl ether folloWed by 
extraction three times With chloroform. The chloroform 
layers Were collected, dried over magnesium sulfate. Evapo 
ration of the solvent a?forded 2.97 g (40%) of (S)-1-(9 
acetoxy-nonyl) -3 -(1-methyl-pyrrolidin-2 -yl)-pyridinium 
bromide (NANNB) as a broWn oil. 1H NMR (300 MHZ, 
CDCl3) 6 9.60 (1H, d), 9.15 (1H, s), 8.47 (1H, d), 8.10 (1H, 
t), 5.01 (2H, t), 4.04 (2H, t), 3.61 (1H, t), 3.29 (1H, t), 2.47 
(2H, m), 2.28 (3H, s), 15442.10 (10, m), 13941.18 (17, m). 
EXAMLE 17 
(S)-1-(11-Acetoxy-undecyl)-3 -(1-methyl-pyrrolidin 
2-yl)-pyridinium bromide (N AUNB) 
To a stirred solution of (S)-nicotine (2.0 ml, 12.5 mmol) 
in AcOH (25 ml) 1,11 dibromoundecane (1.47 ml, 6.2 
mmol) Was added. The mixture Was re?uxed for 3 days. 
After evaporation of the AcOH, the resulting residue Was 
basi?ed using saturated aqueous NaHCO3. The resulting 
aqueous solution Was extracted three times With ethyl ether 
folloWed by extraction three times With chloroform. The 
chloroform layers Were collected, dried over magnesium 
sulfate. Evaporation of the solvent a?forded 2.80 g (36%) of 
(S)-1-(11-acetoxy-undecyl)-3-(1-methyl-pyrrolidin-2-yl) 
pyridinium bromide (NAUNB) as a broWn oil. 1H NMR 
(300 MHZ, CDCl3) 6 9.58 (1H, d), 9.13 (1H, s), 8.46 (1H, 
d), 8.08 (1H, t), 4.99 (2H, t), 4.02 (2H, t), 3.62 (1H, t), 3.28 
(1H, t), 2.48 (2H, m), 2.28 (3H, s), 15342.00 (10, m), 
14141.17 (17, m). 
EXAMPLE 18 
(S)-1-(12-Acetoxy-dodecyl)-3-(1-methyl-pyrrolidin 
2-yl)-pyridinium bromide (NADDNB) 
To a stirred-solution of (S)-nicotine (0.603 ml, 3.75 
mmol) in AcOH (25 ml) 1,12 dibromododecane (0.56 g, 
1.71 mmol) Was added. The mixture Was re?uxed for 3 days. 
After evaporation of the AcOH, the resulting residue Was 
basi?ed using saturated aqueous NaHCO3. The resulting 
aqueous solution Was extracted three times With ethyl ether 
folloWed by extraction three times With chloroform. The 
chloroform layers Were collected, dried over magnesium 
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sulfate. Evaporation of the solvent a?‘orded 0.64 g (26%) of 
(S)-1-(12-acetoxy-dodecyl)-3 -(1-methyl-pyrrolidin-2-yl) 
pyridinium bromide (NADDNB) as a broWn oil. 1H NMR 
(300 MHZ, CDCl3) 6 9.58 (1H, d), 9.14 (1H, s), 8.46 (1H, 
d), 8.08 (1H, t), 5.00 (2H, t), 4.04 (2H, t), 3.62 (1H, t), 3.29 
(1H, t), 2.48 (2H, m), 2.28 (3H, s), 1.55*2.1(10, m), 
14241.19 (17, m); 13C NMR (75 MHZ, CDCl3) 6 171.3, 
144.2, 144.0, 143.0, 128.4><2, 67.2, 64.8, 62.4, 56.9, 40.7, 
36.0, 32.3, 29.7><2, 29.6, 29.5, 29.4, 29.3, 28.8, 26.4, 26.1, 
23.4, 21.3. 
EXAMPLE 19 
[3H]-DA Release Assay 
Rat striatal slices (500 um thickness, 648 mg Wet Weight) 
Were incubated for 30 minutes in Kreb’s bu?er (118 mM 
NaCl, 4.7 mMKCl, 1.2 mM MgCl2, 1.0 mM NaH2PO4, 1.3 
mM CaCl2, 11.1 mM glucose, 25 mM NaHCO3, 0.11 mM 
L-ascorbic acid, and 0.004 mM disodium EDTA; pH 7.4, 
and saturated With 95% O2/ 5% CO2) in a metabolic shaker 
at 340 C. Slices Were rinsed With 15 ml of fresh bu?er and 
incubated for an additional 30 minutes in fresh bu?er 
containing 0.1 uM [3]H-DA (6 slices/3 ml). Subsequently, 
slices Were rinsed With 15 ml of fresh bu?er and transferred 
to a glass superfusion chamber. Slices Were superfused (1.0 
ml/min) for 60 minutes With Kreb’s bu?er containing 
nomifensine (10 uM) and pargyline (10 uM) and maintained 
at 340 C., pH 7.4, With continual aeration (95% O2/5% CO2). 
TWo ?ve minute samples (5 ml each) Were collected to 
determine basal out?oW of [3H]-DA. Chain-modi?ed NONI 
and NDNI analogs Were added to the superfusion bu?er after 
the collection of the second sample and remained in the 
bu?er until 12 consecutive ?ve minute samples Were col 
lected. Subsequently, S-(—)-nicotine (10 uM) Was added to 
the bu?er and an additional 12 consecutive ?ve minute 
samples Were collected. At the end of the experiment, each 
slice Was solubiliZed and the [3H] content of the tissue 
determined. 
Radioactivity in the superfusate and tissue samples Was 
determined by liquid scintillation spectroscopy. Fractional 
release for each sample Was calculated by dividing by the 
total tritium present in the tissue at the time of sample 
collection, and Was expressed as a percentage of total tissue 
tritium. Basal [3H]out?oW Was calculated from the average 
of the tritium collected in the tWo ?ve minute samples just 
before addition of the chain-modi?ed NONI and NDNI 
analog. The sum of the increase in collected tritium resulting 
from either exposure to the test-compound or exposure to 
nicotine in the absence and presence of the test compound 
equaled total [3H]over?oW. [3H]Over?oW Was calculated by 
subtracting the [3H]out?oW during an equivalent period of 
prestimulation from the values in samples collected during 
and after drug exposure. Inasmuch as the radiolabelled 
compounds Were not separated and identi?ed, the tritium 
collected in superfusate is referred to as either [3H]out?oW 
or [3 H]over?oW, rather than as [3H]-DA. [3H]Over?oW 
primarily represents [3H] -DA in the presence of nomifensine 
and pargyline in the superfusion bu?er. 
The chain-modi?ed NONI and NDNI analogs Were evalu 
ated for their ability to evoke [3H] release from rat striatal 
slices at three concentrations (0.1, 1 and 10 uM). In addition, 
the classical competitive nicotinic antagonist DHBE Was 
also examined in this assay for comparison. None of the 
compounds examined at concentrations beloW 10 uM had 
any signi?cant [3H]-DA releasing properties in this assay. 
Since striatal NIC-evoked [3H]-DA release is thought to be 
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mediated through a mechanism involving the putative 
0662* receptor subtype, these compounds do not possess 
signi?cant agonist activity at this subtype. 
The chain-modi?ed NONI and NDNI analogs Were also 
evaluated for their ability to inhibit NIC evoked [3H]-DA 
release. In these experiments, striatal slices Were superfused 
for 60 minutes With various concentrations of the analogs 
prior to NIC (10 pM) exposure. Antagonist activity Was 
evaluated by comparing the NIC-evoked [3H]over?oW in the 
absence and presence of the analogs. The relative order of 
potency of these chain-modi?ed NONI and NDNI analogs 
for inhibition of NIC-evoked [3H]-DA release from rat 
striatal slices is provided in Table 1 by a comparison of their 
IC5O values. 
TABLE 1 
IC5Os for Chain-modi?ed NONI and NDNI Analogs in 
the S—(—)—NIC-evoked PHI-DA Release Assay 
Compound IC5O (pM) 
NONI 0.62 
NDNI >100 
DHBE 3 .60 
NONB-3t 3 .47 
NDNB-4t 0.33 
NONB-3c 2.02 
NDNB-4c 1 .48 
NONB-7e 2.61 
NUNB- 10e 
NCyNB-4 
NCyNB-5 
NCyNB-6 
NONB-3y 1.68 
NDNB-3y 2.59 
NONB-6e7M 1.99 
NONB-7M >100 
NONB-306O 
NANNB 
NADNI 
NADDNB 
EXAMPLE 20 
[3H]-NIC Binding Assay 
Striata from tWo rats Were dissected, pooled, and homog 
eniZed With a Tekmar polytron in 10 volumes of ice-cold 
modi?ed Krebs-HEPES buffer (20 mM HEPES, 118 mM 
NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 
adjusted to pH 7.5). The homogenates Were incubated at 37° 
C. for 5 minutes and centrifuged at 15,000 g for 20 minutes. 
The pellet Was resuspended in 10 volumes of ice-cold 
MilliQ Water, incubated for 5 minutes at 37° C., and cen 
trifuged at 15,000 g for 20 mm. The second pellet Was then 
resuspended in 10 volumes of fresh ice-cold 10% Krebs 
HEPES buffer, incubated at 37° C., and centrifuged at 
15,000 g for 20 minutes. The latter sequence of resuspen 
sion, incubation, and rentrifugation Was repeated. The pellet 
Was froZen under fresh 10% Krebs-HEPES buffer and stored 
at —40° C. until assayed. Upon assay, the pellet Was resus 
pended in the Krebs-HEPES buffer, incubated at 37° C. for 
5 minutes, and centrifuged at 15,000 g for 20 mm. The ?nal 
pellet Was resuspended in 3.6 ml ice-cold MilliQ Water 
Which provided for approximately 200 pg protein per 100 pl 
aliquot. Competition assays Were performed in triplicate in 
a ?nal volume of 200 pl Krebs-HEPES buffer containing 
250 mmol Tris buffer (pH 7.5 at 4° C.). Reactions Were 
initiated by addition of 100 pl of membrane suspension to 3 
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nM [3H]-NIC (50 pl) and one of at least nine concentrations 
of chain-modi?ed NONI and NDNI analog (50 pl). After a 
90 min incubation at 4° C., reactions Were terminated by 
dilution of the samples With 3 ml of ice-cold Krebs-HEPES 
buffer folloWed immediately by ?ltration through Whatman 
GF/B glass ?ber ?lters (presoaked in 0.5% polyethylene 
imine) using a Brandel Cell Harvester. Filters Were rinsed 
three times With 3 ml of ice-cold Krebs-HEPES buffer, 
transferred to scintillation vials, and 5 ml scintillation cock 
tail (Research Products International Corp., Mt. Prospect, 
Ill.) added. Nonspeci?c binding determined in triplicate Was 
de?ned as binding in the presence of 10 pM NIC. Binding 
parameters Were determined using the Weighted, least 
squares nonlinear regression analysis. 
The chain-modi?ed NONI and NDNI analogs Were evalu 
ated for their ability to displace [3H]-NIC binding from rat 
striatal membranes. The results are summariZed in Table 2. 
Furthermore, the displacement by the analogs Was compared 
to that produced by DHBE (Ki:150 nM). 
TABLE 2 
Speci?c Binding of [3H]—NIC to Rat Striatal Nicotinic 
Acetylcholine Receptors in the Presence of chain 
modi?ed NONI and NDNI analogs 
Compound K; (pM)“ 
NONI 20 
NDNI 0.093 
DHBE 0.15 
NONB-3t 3.97 
NDNB-4t 0.32 
NONB-3c 0.086 
NDNB-4c 7.79 
NONB-7e 0.45 
NCyNB-4 7.20 
NCyNB-5 5.54 
NCyNB-6 4.56 
NONB-3y 0.20 
NDNB-3y 0.81 
NONB-6e7M 0.45 
NONB-7M 0.44 
NONB-306O 1.20 
NANNB 
NADNI 
NADDNB 
3Data are expressed as fmol/mg of protein of at least 3 independent 
experiments. Speci?c binding is calculated as the difference between the 
total binding of3 nM [3H]—NIC to the receptors alone and nonspeci?c 
binding in the presence of 10 pM nicotine. 
EXAMPLE 21 
[3 H] -MLA Binding Assay 
Rat brain tissue (Without cortex, striatum and cerebellum) 
Was homogeniZed With a Tekmar Polytron (setting 40) in 20 
volumes of ice-cold hypotonic buffer (2 mM HEPES, 14.4 
mM NaCl, 0.15 mM KCl, 0.2 mM CaCl2 and 0.1 mM 
MgSO4, pH:7.5). The homogenate Was incubated at 37° C. 
for 10 minutes and centrifuged at 25,000><g for 15 minutes 
at 40° C. The pellet Was Washed 3 times more by resuspen 
sion in the 20 volumes of the same buffer and centrifugation 
at the above parameters. The ?nal pellet Was stored at —20° 
C. under 4.6 ml of the incubation buffer and Was suspended 
just before the incubation With radioligand. 
The binding of [3H]methyllycaconitine ([3H]MLA), a 
probe for the (x7 neuronal nicotinic acetylcholine receptor 
subtype, Was determined using a modi?cation of the method 
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of Davies et al., “Characterisation of the binding of [3H] 
methyllycaconitine: a neW radioligand for labelling (x7-type 
neuronal nicotinic acetylcholine receptors”, Neuropharma 
cology, 38, 6794690 (1999). [3H]-MLA (25.4 Ci/mmol) Was 
purchased from Tocris Cookson Ltd., Bristol, UK. Binding 
Was performed in duplicate, in a ?nal volume of 250 ML of 
the incubation medium, containing 20 mM HEPES, 144 mM 
NaCl, 1.5 mM KCl, 2 mM CaCl2, 1 mM MgSO4 and 0.05% 
BSA, pH:7.5. Reaction Was initiated by the addition of 100 
pl of membrane suspension to the samples containing a 
desired concentration of test compounds and 2.5 nM [3H] 
MLA (?nal concentration) and incubated for 2 hours at room 
temperature. Total binding Was measured in the absence of 
unlabelled ligand, and nonspeci?c binding Was determined 
in the presence of 1 uM unlabelled MLA. The binding 
reaction Was terminated by dilution of samples With 3 ml of 
ice-cold incubation buffer folloWed by immediate ?ltration 
through presoaked in 0.5% polyethylenimine glass ?ber 
?lters (S&S, grade #32) using a Brandel harvester system. 
Filters Were rinsed three times With 3 ml of ice-cold buffer, 
transferred to scintillation vials and 4 ml of scintillation 
cocktail Was added. Protein Was measured using the Brad 
ford dye-binding procedure With bovine serum albumin as 
the standard. 
In order to determine if these compounds have affinity at 
the (X7 receptor subtype, the chain-modi?ed NONI and 
NDNI analogs Were evaluated for their ability to displace 
[3H] -MLA binding from rat brain membranes, as a re?ection 
of their interaction With the (X7 receptor (Table 3). In 
addition, the classical (X7 receptor antagonist ot-bungaro 
toxin Was also examined in this assay for comparison. 
ot-Bungarotoxin afforded a K,- value of 7.2 nM in the above 
assay. The results from the competition binding assay 
shoWed that NCyNB-4, NCyNB-5, and NCyNB-6 had Ki’s 
of 30.3 11M, 88.7 11M, and 42.7 11M, respectively. None of the 
other chain-modi?ed NONI and NDNI analogs possessed 
any signi?cant binding af?nity in the [3H]-MLA assay at 
concentration>100 11M. 
The purpose of the above description and examples is to 
illustrate some embodiments of the present invention With 
out implying any limitation. It Will be apparent to those of 
skill in the art that various modi?cations and variations may 
be made to the composition and method of the present 
invention Without departing from the spirit or scope of the 
invention. All patents and publications cited herein are 
incorporated by reference in their entireties. 
What is claimed is: 
1. A compound including resolved enantiomers and dias 
tereoisomers thereof selected from a formula consisting of 
formula (VI): 
(V1) 
Wherein 
Q is methylene; 
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R1 is selected from the group consisting of hydrogen, 
loWer straight chain or branched alkyl, cycloalkyl, 
substituted cycloalkyl, aryl and aralkyl; 
R2, Z1 and Z4 are each independently selected from the 
group consisting of hydrogen, loWer alkyl, loWer 
branched alkyl, loWer alkenyl, and loWer branched 
alkenyl; 
A and B are carbon; 
R3, R4, Z2 and Z3 are each independently selected from 
the group consisting of hydrogen; alkyl; substituted 
alkyl; cycloalkyl; substituted cycloalkyl; substituted 
alkenyl; substituted alkenyl; alkynyl; substituted alky 
nyl; aryl; substituted aryl; alkylaryl; substituted alky 
laryl; arylalkyl; substituted arylalkyl; arylalkenyl; sub 
stituted arylalkenyl; arylalkynyl; substituted 
arylalkynyl; 
R5 is selected from the group consisting of alkyl; substi 
tuted alkyl; cycloalkyl; substituted cycloalkyl; alkenyl; 
substituted alkenyl; alkynyl; substituted alkynyl; aryl; 
substituted aryl; arylalkyl; substituted arylalkyl; aryla 
lkenyl; substituted arylalkenyl; arylalkynyl; substituted 
arylalkynyl, With the proviso that R5 of R optical 
isomer of Formula (VI) is not iCH2OH When A and 
B are carbon, and R5 of the S optical isomer of Formula 
(VI) is not hydrogen, 4CH2NH2 or 4CH2Ph When A 
and B are carbon; 
R6 is hydrogen; and 
Y is selected from the group consisting of 2C1, 2Br, 2I, 
2HSO4, S02, 2CH3SO3, 2p-TsO and 2CF3SO3. 
2. The compound according to claim 1, Wherein said 
compound is (S)-trans-3-(1-methyl-pyrrolidin-2-yl)-1-oct 
3-enyl-pyridinium bromide hydrobromide salt. 
3. The compound according to claim 1, Wherein said 
compound is (S)-trans-1-dec-4-enyl-3-(1-methyl-pyrrolidin 
2-yl)-pyridinium bromide. 
4. The compound according to claim 1, Wherein said 
compound is (S)-cis-3-(1-methyl-pyrrolidin-2-yl)-1-oct-3 
enyl-pyridinium bromide hydrobromide salt. 
5. The compound according to claim 1, Wherein said 
compound is (S)-cis-1-dec-4-enyl-3-(1-methyl-pyrrolidin-2 
yl)-pyridinium bromide hydrobromide salt. 
6. The compound according to claim 1, Wherein said 
compound is (S)-1-dec-9-enyl-3-(1-methyl-pyrrolidin-2-yl) 
pyridinium bromide. 
7. The compound according to claim 1, Wherein said 
compound is (S)-1-(6-cyclobutyl-hexyl)-3-(1-methyl-pyrro 
lidin-2-yl)-pyridinium bromide hydrobromide salt. 
8. The compound according to claim 1, Wherein said 
compound is (S)-1-(6-cyclopentyl-hexyl)-3-(1-methyl-pyr 
rolidin-2-yl)-pyridinium bromide hydrobromide salt. 
9. The compound according to claim 1, Wherein said 
compound is (S)-1-(6-cyclohexyl-hexyl)-3-(1-methyl-pyr 
rolidin-2-yl)-pyridinium bromide hydrobromide salt. 
10. The compound according to claim 1, Wherein said 
compound is (S)-1-(7-methyl-oct-6-enyl)-3-(1-methyl-pyr 
rolidin-2-yl)-pyridinium bromide hydrobromide. 
11. The compound according to claim 1, Wherein said 
compound is (S)-1-(7-methyl-octyl)-3-(1-methyl-pyrroli 
din-2-yl)-pyridinium bromide hydrobromide salt. 
12. The compound according to claim 1, wherein R1 is 
hydrogen or straight chain or branched alkyl having 1410 
carbons, R5 is a branched or non-branched C(Cl9 alkyl 
having 4419 carbons, cycloalkyl, alkenyl, alkynyl, aryl, 
arylalkyl, arylalkenyl or arylalkynyl; and Y is 2Br or 21. 
13. The compound according to claim 1, wherein R1 is 
methyl, ethyl, isopropyl or isobutyl; R2 is hydrogen; and R3 
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and R4 are individually hydrogen, halogen, alkyl or alkyol, 
R5 is a branched or non-branched C4£19 alkyl having 4*19 
carbons, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, aryla 
lkenyl or arylalkynyl; Z1, Z2, Z3 and Z4 hydrogen; Y is 2Br 
or 21. 
14. The compound according to claim 1, wherein R1 is 
methyl; R2 is hydrogen; and R3 and R4 are individually 
hydrogen, halogen, alkyl or alkyol, R5 is a branched or 
30 
non-branched C4£19 alkyl having 4*19 carbons, 
cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl or 
arylalkynyl; Z1, Z2, Z3 and Z4 are hydrogen; andY is 2Br or 
21. 
15. The compound according to claim 1, Wherein said 
compound is substantially optically pure. 
* * * * * 
